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Summary 
Lung cancer is the leading cause of cancer-related death worldwide, 
underscoring the importance of understanding the molecular mechanisms 
responsible of lung cancer initiation, progression and metastasis. One major 
characteristic and important diagnostic criterion for lung cancer and other 
neoplasias is the aberrant nuclear structure. The nuclear lamins, which are the 
structural component of nuclear envelope, has been shown to be critical 
determinants of nuclear structure, shape and genome integrity.  
In the present study, we demonstrate a critical role of lamin B1 loss in facilitating 
lung cancer development, migration and metastasis. First, we observed 
significant lower levels of lamin B1 in human lung cancer tissues in comparison 
with normal lung tissues. Furthermore, lamin B1 haploinsufficiency is sufficient 
to induce spontaneous pulmonary tumor formation in mice model, suggesting 
that loss of lamin B1 promotes lung cancer initiation. Moreover, lamin B1 
depletion triggers epithelial-mesenchymal transition (EMT) and facilitates 
cancer cell migration and metastasis via upregulating the receptor tyrosine 
kinase RET. RET upregulation upon lamin B1 silencing further activates p38 
signaling pathway. Targeting both RET and its downstream target p38 
repressed lamin B1 depletion mediated cancer cell migration and metastasis. 
Consistently, lamin B1 and RET expressions show inverse correlation in lung 
cancer patients. 
Mechanistically, we show that loss of lamin B1 results in global decrease in 
H3K27me3 and reduces the occupancy of H3K27me3 at Ret promoter by 
disrupting the recruitment of methyltransferase EZH1 and EZH2 to the 
chromatin and Ret promoter, thus leading to the transcriptional activation of Ret 
gene. Taken together, our data demonstrate a role of lamin B1 as a tumor 
suppressor in lung cancer by epigenetically repressing the RET expression, 
prospecting a novel therapeutic strategy by targeting RET in the treatment of 
lung cancer patients with lamin B1 loss. 
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Zusammenfassung  
Lungenkrebs ist weltweit die Hauptursache für krebsbedingte Todesfälle. Daher 
ist es sehr wichtig die Bedeutung des Verständnisses der molekularen 
Mechanismen, die für den Beginn, die Progression und die Metastasierung von 
Lungenkrebs verantwortlich sind, zu verstehen. Ein wichtiges 
charakteristisches und diagnostisches Kriterium für Lungenkrebs und andere 
Neoplasien ist die abweichende Kernstruktur. Es hat sich gezeigt, dass die 
nuklearen Lamine, die entscheidenden Determinanten der Kernstruktur, -form 
und -integrität des Genoms sind. 
In der aktuellen Studie zeigen wir, dass die Depletion von Lamin B1 eine 
entscheidende Rolle bei der Krebsentwicklung, der Migration und der 
Metastasierung spielt. Erstens beobachteten wir einen signifikant niedrigeren 
Gehalt an Lamin B1 in menschlichen Lungenkrebsgeweben als das normale 
Lungengewebe. Darüber hinaus reicht die Lamin-B1-Haploinsuffizienz aus, um 
die spontane Lungentumorbildung im Mäusemodell zu induzieren, was darauf 
hindeutet, dass der Verlust von Lamin-B1 den Beginn und die Progression von 
Lungenkrebs fördert. Des Weiteren löst eine Lamin B1-Depletion den Epithelial-
Mesenchymalen-Übergang (EMT) aus und fördert die Migration und 
Metastasierung von Krebszellen, indem die Rezeptor-Tyrosinkinase-RET 
hochreguliert wird. Die RET-Hochregulierung bei der Depletion von Lamin B1 
aktiviert den p38-Signalweg. Das Targeting sowohl auf RET als auch auf sein 
nachgeschaltetes Ziel p38 unterdrückte die Lamin B1-Depletion die vermittelte 
Migration und Metastasierung von Krebszellen. Konsistent zeigen Lamin-B1- 
und -RET-Expressionen eine inverse Korrelation bei Lungenkrebspatienten.  
Mechanistisch zeigen wir, dass der Verlust von Lamin B1 zu einer globalen 
Abnahme von H3K27me3 führt und die Belegung von H3K27me3 am Ret-
Promotor verringert, indem die Rekrutierung von Methyltransferase EZH1 und 
EZH2 für das Chromatin und den Ret-Promotor unterbrochen wird, was zur 
transkriptionellen Aktivierung des Ret-Gens führt. Zusammengenommen 
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zeigen unsere Daten eine Rolle von Lamin B1 als Tumorsuppressor bei 
Lungenkrebs durch epigenetische Unterdrückung der RET-Expression. Dies 
könnte neue therapeutische Wege eröffnen, indem RET bei der Behandlung 
von Lungenkrebspatienten mit Lamin B1-Depletion eingesetzt wird. 
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1. Introduction 
1.1 Lung cancer types and markers 
Lung cancer is one of the most frequently diagnosed cancers and results in the 
largest number of cancer related deaths worldwide (Ferlay et al., 2015; Siegel 
et al., 2013). Lung cancer is classified into two different groups: Non-small cell 
lung cancer (NSCLC) and small cell lung cancer (SCLC), based on the 
morphological features of the cancer cells. NSCLC, which accounts for 
approximately 85% of all the lung cancer cases, is histologically divided into 
three different subtypes: adenocarcinoma (AD), squamous cell carcinoma 
(SCC) and large-cell carcinoma. SCLC, which is considered as a 
neuroendocrine carcinoma (Park et al., 2011a; Wistuba et al., 2001), represents 
the remaining 15% of all lung cancer cases (Travis et al., 2013). In contrast to 
NSCLC, SCLC is characterized by an aggressive clinical course, rapid growth 
and early metastasis (Karachaliou et al., 2016).  
Biological markers are universally used to identify different lung cancer 
subtypes in order to improve diagnostic efficiency. Napsin A is shown as a 
specific marker for lung adenocarcinoma (Turner et al., 2012). Napsin A, in 
combination with the pulmonary marker thyroid transcription factor-1 (TTF1), is 
used to differentiate primary lung adenocarcinoma from metastatic carcinoma 
in the lung (Ye et al., 2011). In addition, CK7+/CK20- pattern is also used to 
characterize lung adenocarcinoma (Khayyata et al., 2009; Kummar et al., 2002; 
Su et al., 2006). Cytokeratin5/6 (CK5/6) and p63 are specific markers for 
identifying SCC (Khayyata et al., 2009; Kim et al., 2013). SCLC originates from 
neuroendocrine cells and overexpresses neuroendocrine markers, including 
calcitonin gene-related peptide (CGRP) (Sutherland et al., 2011), 
Synaptophysin (SYP) (Jensen et al., 1990), achaete scute homolog 1 (ASCL1) 
(Arriola et al., 2008), NCAM (CD56) (Kontogianni et al., 2005), pro-gastrin-
releasing peptide (ProGRP) (Molina et al., 2004; Nisman et al., 2009), thus 
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these markers are helpful in differentiating SCLC from NSCLC together with 
morphological differences. 
1.2 Cancer metastasis 
1.2.1 Metastatic cascade 
The major cancer related mortality is due to the metastasis of primary tumor 
cells, which is a complex process that remains only partially understood at the 
biochemical and molecular level. By definition, cancer metastasis is the 
movement of cancer cells from the site where cancer originate (primary site), 
to grow in different sites (secondary sites) of the body. Cancer metastasis 
occurs through a series of sequential steps (Figure 1). First, with the help of 
tumor-associated macrophages, cancer cells move from the primary tumor site 
to the vasculature through invading the stroma and adjacent tissues. Then 
cancer cells transmigrate through endothelial cell junctions into the blood 
vessels. Once entered the bloodstream, cancer cells are transported through 
the circulatory system and finally attach to the endothelial wall of a blood vessel 
at the secondary site. Next, cancer cells transmigrate through the endothelial 
barrier. Although most of the cancer cells die after extravasation, the surviving 
 
 
Figure 1. Process of cancer metastasis (Reymond et al., 2013). 
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cancer cells start to proliferate immediately or after a period of cellular dormancy, 
and then form metastases in their new location (Hunter et al., 2008; Mehlen 
and Puisieux, 2006; Reymond et al., 2013). 
Since metastases are responsible for approximately 90% of all human cancer 
deaths (Mehlen and Puisieux, 2006), dissecting the biological mechanism of 
metastasis at a molecular level is of great importance to metastasis-directed 
therapy. 
1.2.2 Epithelial–mesenchymal transition 
1.2.2.1 Role of epithelial–mesenchymal transition in cancer metastasis 
Epithelial–mesenchymal transition (EMT) is a process by which an epithelial 
cell converts into a cell with mesenchymal phenotype that acquire migratory 
and invasive capabilities (Kalluri and Weinberg, 2009). Activation of an EMT 
program is a critical mechanism for acquiring malignant phenotypes by 
epithelial cancer cells (Kalluri and Weinberg, 2009; Thiery, 2002). More 
importantly, EMT is widely regarded as the major contributor to cancer 
metastasis (Heerboth et al., 2015; Kalluri and Weinberg, 2009). Therefore, 
uncovering the biological mechanism and molecular factors which lead to EMT 
is of vital importance for establishing therapeutic approaches targeting cancer 
metastasis.  
1.2.2.2 Cellular events and change of molecular markers during EMT 
During the process of EMT (Figure 2), the epithelial cells stepwise deconstruct 
cell–cell junctions (Huang et al., 2012; Lamouille et al., 2014; Yilmaz and 
Christofori, 2009); lose apical–basal polarity and gain front–rear polarity (Huang 
et al., 2012; Lamouille et al., 2014); reorganize epithelial cytoskeletal 
architecture into one that facilitate cell elongation and directional motility 
(Lamouille et al., 2014; Thiery and Sleeman, 2006; Yilmaz and Christofori, 
2009), by which cells acquire invasive and migratory ability. The motility of these 
cells is enhanced by forming lamellipodia, filopodia and invadopodia (Lamouille 
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et al., 2014; McNiven, 2013; Ridley, 2011). The whole process of EMT can be 
characterized by changing of various cell markers, including loss of epithelial 
markers, such as E-cadherin, ZO-1, cytokeratin and so forth; as well as 
acquisition of mesenchymal markers, such as N-cadherin, Fibronectin, 
Vimentin and so on. Among these, loss of E-cadherin is the most intensively 
investigated one, and is considered as fundamental event for EMT.  
E-cadherin is a transmembrane protein in charge of cell- cell adherent junction 
via forming extracellular interaction with another E-cadherin on neighboring 
cells (Huang et al., 2012; Lamouille et al., 2014). Intracellularly, cytoplasmic 
part of E-cadherin links to actin cytoskeleton in an α- or ß-catenin dependent 
manner (Heerboth et al., 2015; Tian et al., 2011). Tight cell-cell junctions 
assemble cell clusters and tissues together, thus E-cadherin depletion and the 
subsequent destruction of cell-cell adherent junctions potentiate individual cells 
to migrate, thereby initiates cancer metastasis. Intensive efforts have been put 
by scientists to elucidate the mechanisms by which E-cadherin is 
downregulated during EMT. One of the most well accepted mechanisms is the 
binding of various EMT transcription factors, such as Snail (Batlle et al., 2000; 
Cano et al., 2000), Slug (Bolos et al., 2003; Medici et al., 2008), Twist (Dave et 
al., 2011; Yang et al., 2010), Zeb (Graham et al., 2008; Sanchez-Tillo et al., 
 
 
 
Figure 2. Morphological and phenotypic changes of cells undergo EMT and the 
representative molecular cell markers used to characterize (Kalluri and Weinberg, 
2009). 
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2010), to the E-cadherin promoter, that transcriptionally represses E-cadherin 
gene. Moreover, these transcription factors also activate several mesenchymal 
genes (Lamouille et al., 2014). For instance, Twist is shown to induce the 
transcription of N-cadherin (Alexander et al., 2006). In addition, multiple cell 
signaling pathways collaborate in stimulating the expression of E-cadherin-
repressing transcription factors, thereby promoting EMT through inhibiting 
transcription of E-cadherin gene (Lamouille et al., 2014).  
1.2.3 Cell signaling pathways that regulate EMT and cancer metastasis 
1.2.3.1 The role of RET receptor tyrosine kinase in cancer metastasis 
RET is a member of the receptor tyrosine kinase family, which plays a critical 
role in cancer invasion and metastasis. The binding of GDNF family ligands 
(GDNF, NTRN, ARTN and PSPN) to GFRA family co-receptors of RET (GFRα1, 
GFRα2, GFRα3 and GFRα4) triggers dimerization of RET and its co-receptor 
 
 
Figure 3. Molecular structure of RET receptor tyrosine kinase and its co-receptors, 
GFRα family members with their GDNF family ligands. RET has not direct binding 
ligand, so its activation is triggered by the binding of GDNF family ligands with GFRα 
family members. GFRα is the co-receptor of RET, the ligand-bound GFRα will 
heterodimerize with RET, thereby trigger autophosphorylation (P) and activate the 
downstream targets (Mulligan, 2014). 
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GFRα (Figure 3), thereby leading to kinase activation and stimulation of 
downstream signaling pathways, thus influencing cancer cell survival, 
proliferation, migration and metastasis (Mulligan, 2014). The activation of RET 
and its downstream signaling pathway has been widely shown to facilitate 
cancer cells invasion and metastasis. For instance, RET was shown to trigger 
migration and metastasis of estrogen receptor positive breast cancer cells by 
activating FAK-STAT3 signaling pathway in a cytokine IL-6 dependent manner 
(Gattelli et al., 2013). Besides, the activation of RET promotes pancreatic tumor 
cell migration and perineural invasion by activating Ras-Raf-MEK-ERK and the 
phosphatidylinositol 3-kinase pathways (Veit et al., 2004) 
In addition to ligand-induced RET activation, gain-of-function mutations of RET, 
which lead to constitutive activation, are also discovered in several types of 
human cancers. For instance, KIF5B-RET fusion was frequently observed in 
patients with lung adenocarcinoma and the tumor cells expressing this fusion 
are sensitive to RET inhibitor (Kohno et al., 2012). Moreover, another chimeric 
oncogene RET/PTC triggers the formation of an autocrine loop involving 
osteopontin and its cell surface receptors CD44 by transcriptionally activating 
osteopontin gene, thereby influencing cell–cell and cell–matrix interactions and 
promoting invasion, migration and metastasis of thyroid carcinoma cells 
(Castellone et al., 2004; Guarino et al., 2005). 
1.2.3.2 The role of p38 MAPK signaling pathway in EMT and metastasis 
Activation of RET activates p38 MAPK signaling pathway (Fonseca-Pereira et 
al., 2014; Ibiza et al., 2016; Zhao et al., 2009), which regulates EMT and cancer 
metastasis through different mechanisms. It has been shown that MAPK p38 
signaling pathway regulates EMT and metastasis in both TGFß-dependent and 
-independent ways (del Barco Barrantes and Nebreda, 2012; Derynck and 
Zhang, 2003; Moustakas and Heldin, 2005). Moreover, p38 MAPK stabilize 
Twist1 protein by phosphorylating it and enabling its capability to trigger EMT 
and metastasis (Hong et al., 2011). Furthermore, activated p38 contributes to 
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RKIP depletion-induced EMT by enhancing phosphorylation of GSK3β, in turn 
enhancing the protein level of β-catenin, Snail and Slug (Al-Mulla et al., 2011). 
In addition, p38α activates hypoxia-inducible factor 1α (HIF1α) under the 
condition of hypoxia, thereby inducing EMT and metastasis (Emerling et al., 
2005). 
Other than EMT, p38 MAPK signaling pathway regulates cancer metastasis 
also by affecting other steps of the process, such as by inducing invasion, 
extravasation and formation of pre-metastatic niche (del Barco Barrantes and 
Nebreda, 2012). For instance, activated p38 MAPK induces ECM remodeling 
by increasing the expression of MMP1, MMP3 and MMP13, thereby promoting 
cancer cell invasion (del Barco Barrantes and Nebreda, 2012; Johansson et al., 
2000; Park et al., 2011b). Futhermore, the interaction between colon cancer 
cells and endothelial cells triggers p38 MAPK activation in both types of cells, 
in turn increasing transendothelial permeability, thus facilitating cancer cells 
extravasation (Tremblay et al., 2006). In addition, activation of p38 MAPK 
pathway also contributes to CXCR4 and VEGFR1 mediated recruitment of 
BMDCs, which facilitates cancer cell metastasis by promoting pre-metastatic 
niche formation (Hiratsuka et al., 2011).  
1.2.3.3 Other cell signaling pathways that regulate EMT and cancer metastasis 
TGFß /SMAD is one of the most well-known signaling pathways contributing to 
EMT and metastasis. TGFß enhances cancer invasion and metastasis by 
stimulating the expression and secretion of MMP-2 and MMP-9 (Hagedorn et 
al., 2001). Binding of TGFß to its receptors activates their intracellular target 
SMADs, which finally translocate into nuclei and regulate transcription of EMT 
and cancer metastasis related genes (Feng and Derynck, 2005; Massague, 
2012). Besides, it has been shown that EMT transcription factors cooperate 
with SMADs in response to TGFß stimulation (Lamouille et al., 2014). For 
instance, Snail collaborates with SMAD3-SMAD4 to repress transcription of E-
cadherin gene, thus inducing EMT and cancer metastasis (Vincent et al., 2009). 
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In addition, TGFß mediated SMADs activation also directly induces the 
expression of a variety of EMT transcription factors, including Snail (Hoot et al., 
2008), Slug (Morita et al., 2007), Zeb (Shirakihara et al., 2007), Twist (Kang et 
al., 2003).  
 
 
Figure 4. Cell signaling pathways implicated in EMT (Lamouille et al., 2014). 
 
In addition to its direct role in repressing E-cadherin expression, TGFß signaling 
pathway also indirectly contributes to EMT by activating other cell signaling 
pathways (Figure 4). For example, TGFß leads to activation of PI3K/AKT 
signaling pathway, thus results in activation of both mTOR1 and mTOR2. Both 
mTOR1 and mTOR2 stabilize Snail expression, thereby repressing E-cadherin 
expression and trigger EMT (Bachelder et al., 2005; Lamouille et al., 2012). In 
addition, activation of PI3K/AKT signaling pathway enhances expression of 
filopodia, which greatly elevates motility of cancer cells (Yang et al., 2004). 
Moreover, Notch signaling pathway also plays an important role in promoting 
cancer metastasis through enhancing secretion of Interleukin 6 (IL-6) by Notch 
ligand Jagged1 (Guo et al., 2014; Sethi et al., 2011).  
Other factors that act through receptor tyrosine kinases (RTKs) have also been 
shown to induce EMT by activating specific downstream signaling pathways 
(Figure 4). For example, hepatocyte growth factor (HGF) induces Snail 
expression by activating ERK MAPK pathway and by stimulating the binding of 
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early growth response 1 (EGR1) to the promoter of Snail gene (Grotegut et al., 
2006). In addition to Snail, Slug expression can be also induced by HGF 
(Savagner et al., 1997). Besides, epidermal growth factor (EGF) induces Snail 
(Lu et al., 2003) or Twist (Lo et al., 2007) expression which results in loss of E-
cadherin, thereby triggering EMT. Furthermore, insulin-like growth factor 1 
(IGF1) activates its receptor and downstream signaling pathway, which in turn 
increases Snail expression, thus repressing E-cadherin expression and 
inducing EMT (Kim et al., 2007). Moreover, WNT signaling pathway also plays 
a key role in promoting EMT and metastasis. The binding of WNT ligands with 
Frizzled receptors prevents GSK3ß from phosphorylating ß-catenin, thereby 
stabilizing the function of ß-catenin. Once stabilized, ß-catenin regulates the 
expression of Snail gene (Lamouille et al., 2014; Niehrs, 2012). In addition, 
platelet-derived growth factor (PDGF) induces nuclear localization of ß-catenin, 
thereby reducing E-cadherin level, thus promoting EMT (Yang et al., 2006).  
1.2.4 Other regulators of EMT and cancer metastasis 
The genetic control and biochemical determinants underlying the acquisitions 
of invasive and metastatic phenotype of cancer cells have been intensively 
investigated, and many factors have been validated to facilitate metastasis.  
1.2.4.1 Chemokines and their receptors 
Chemokines are small molecular proteins that interact with the G-protein-
coupled chemokine receptors. It has been shown that chemokines play key 
roles in promoting cancer metastasis (Muller et al., 2001; Sarvaiya et al., 2013). 
For instance, CXCL12 and its receptor CXCR4 have been widely shown to 
initiate and mediate metastasis in a variety of human cancers, including lung 
(Phillips et al., 2003; Su et al., 2005), breast (Li et al., 2004; Liang et al., 2004; 
Wendt et al., 2008) colorectal cancer (Speetjens et al., 2009; Wendt et al., 2006) 
and so on. Cancer cells tend to highly express CXCR4, which leads them 
migrate to the organs with high level of CXCL12, including lung, brain, lymph 
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nodes, liver, and bone marrow (Bruce et al., 1970; Muller et al., 2001; Sarvaiya 
et al., 2013). In addition, CCR7-CCL19/CCL21 axis (Muller et al., 2006; 
Takanami, 2003) as well as CCR9-CCL25 (Amersi et al., 2008; Johnson-
Holiday et al., 2011; Singh et al., 2011), CCR10-CCL27/CCL28 (Muller et al., 
2001; Simonetti et al., 2006), CXCR3-CXCL9, CXCL10, CXCL11 (Cambien et 
al., 2009; Pradelli et al., 2009) and CXCR5-CXCL13 axis (Airoldi et al., 2008; 
Lopez-Giral et al., 2004) have also been shown to facilitate cancer metastasis. 
1.2.4.2 Angiogenesis 
Angiogenesis increases the chance for cancer cells to intravasate by providing 
larger vascular areas (Moserle and Casanovas, 2013). Besides, vascular 
endothelial growth factor (VEGF), which is essential for angiogenesis 
(Carmeliet, 2005), facilitates cancer cells intravasation and extravasation by 
increasing vascular permeability (Bates, 2010; Liu et al., 2002; Moserle and 
Casanovas, 2013). Furthermore, it has been shown that VEGFR1-expressing 
bone marrow-derived hematopoietic progenitor cells migrate to tumor-specific 
pre-metastatic sites and pave the way for the incoming cancer cells by forming 
the pre-metastatic niche and promoting vascularization (Kaplan et al., 2005). 
1.2.4.3 Extracellular matrix (ECM) remodeling 
A successful metastasis requires metastatic cancer cells to survive, colonize 
and proliferate at a distant site (Hunter et al., 2008; Mehlen and Puisieux, 2006), 
therefore, interaction between the disseminated cancer cells and the new 
microenvironment is of great importance. ECM is a non-cellular structure 
composed of diverse proteins, such as collagen, proteoglycans, glycoproteins 
and so forth. 
As an important element of metastatic niche, ECM remodeling and the 
changing in cell-ECM interaction are critical to the initiation and progression of 
EMT (Lamouille et al., 2014) and play key roles in the invasion and metastatic 
colonization of cancer cells in the distant sites (Hoye and Erler, 2016). For 
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instance, integrin α3ß1 is indispensable for TGFß mediated EMT, by 
coordinating cross-talk between E-cadherin/β-catenin and TGFß/Smad 
signaling pathways (Kim et al., 2009). Additionally, the expression of integrin 
α5ß1 and its interaction with fibronectin are induced by the TGFß-stimulated 
EMT (Maschler et al., 2005; Mise et al., 2012). Furthermore, the interaction of 
Collagen type I with ß1-containing integrins facilitates pancreatic cancer cells 
invasion and metastasis via disrupting E-cadherin mediated cell-cell adhesion 
(Koenig et al., 2006). Moreover, the binding of integrin αvß6 to the TGFß 
isoforms activates TGFß-mediated EMT and cancer cell metastasis (Sheppard, 
2005). 
MMP-3, MMP-7 and MMP-9 are known to cleave E-cadherin into small 
fragments, thereby inhibiting E-cadherin and promoting EMT in an EGFR 
signaling pathway dependent manner (David and Rajasekaran, 2012; Maretzky 
et al., 2005; Najy et al., 2008; Noe et al., 2001). In addition to the cleaving 
function on E-cadherin, MMP3 upregulates Snail by elevating the cellular level 
of reactive oxygen species (ROS), which plays a key role in stimulating 
expression of Snail gene (Radisky et al., 2005). In addition, MMP9 also 
cooperates with Snail to induce EMT (Lin et al., 2011). 
1.2.4.4 Hypoxia 
Hypoxia, a well-known feature of tumor microenvironment, is emerging as a key 
factor in the regulation of cancer metastasis. Hypoxia activates HIF signaling, 
thereby facilitating cancer metastasis by various mechanism. 
Hypoxia and HIF signaling activation facilitate cancer cells resistance to 
cytotoxic T lymphocyte-mediated immune attack (Palazon et al., 2014; Rankin 
and Giaccia, 2016) and natural killer cell-mediated antitumor responses 
(Baginska et al., 2013; Messai et al., 2014), thereby contributing to cancer cell 
survival and metastasis. Furthermore, HIF1α induces Snail and Twist 
expression by directly binding to their promoter (Higgins et al., 2007; Liu et al., 
2014; Yang et al., 2008), thereby facilitating EMT and cancer metastasis.  
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It has been shown that hypoxia, on the one hand, facilitates metastasis via 
regulating ECM remodeling in the metastatic niche, on the other hand, 
regulates ECM by elevating the MMPs expression in cancer cells (Gilkes et al., 
2014). Moreover, hypoxia results in modification of collagen matrix, thus leads 
to recruitment of bone marrow–derived cells (Gilkes et al., 2014; Rankin and 
Giaccia, 2016), which finally stimulate cancer cell metastasis via various 
mechanism, including secreting chemokines which recruit and guide cancer cell, 
as well as stimulating cancer cell extravasation (Gao et al., 2008; Kaplan et al., 
2005; Rankin and Giaccia, 2016; Wong et al., 2011a).  
In addition, hypoxia induces expression of VEGF-A, thereby stimulate 
angiogenesis and cancer metastasis (Joyce and Pollard, 2009; Maxwell et al., 
1997). 
1.2.4.5 Epigenetic control of EMT 
Increasing amount of studies have been indicating that epigenetic regulation of 
E-cadherin level as well as EMT transcription factors expression and function 
play pivotal roles in modulating EMT process, thus regulating cancer cells 
migration and metastasis (Sun and Fang, 2016). The mechanism by which 
epigenetic events influence EMT and cancer metastasis will be discussed 
detailedly in Chapter 1.5.   
1.3 Changes in nuclear structure in cancer cells 
Despite of well-understood cellular and molecular changes taking place in 
cancer progression and metastasis, the clinical diagnosis of cancer still largely 
based on the cancer specific morphological changes, especially the alterations 
of nuclear structure (Zink et al., 2004). The most frequent observed 
morphological alterations of nuclear structure in cancer cells consist of changes 
in nuclear matrix, irregular nuclear shape and size, changes in the quantity and 
the size of nucleoli as well as in the chromatin structure and organization (Zink 
et al., 2004) (Figure 5).  
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Figure 5. Nuclear structure in normal and cancer cells (Zink et al., 2004). a. Nucleus 
of normal cell. b. nucleus of cancer cell. Purple, nuclear lamina; green, 
heterochromatin; yellow, nucleoli; red, promyelocytic leukaemia (PML) body; pink, 
perinucleolar compartment (PNC) 
 
1.3.1 Nuclear shape and size in cancer cells 
Change of nuclear shape is an important morphological alteration observed 
frequently in cancer progression. In contrast to the normal nucleus with a 
regular rounded or oval shape, the nucleus of a cancer cell becomes odd with 
irregular shape and begin to fold (Zink et al., 2004) (Figure 5). In fact, changes 
in nuclear shape has been used as an important diagnostic feature in identifying 
various cancer cells. For example, checking the nuclear shape with Pap smear 
has been widely applied in early detection of cervical cancer (Webster et al., 
2009). In addition, deformed nuclei with malleable appearance are also 
regarded as a key feature for diagnosing SCLC (Zink et al., 2004). In contrast 
to the frequent observation in cancer cells, the exact role of altered nuclear 
shape in cancer cells and its potential cause are still poorly understood. Some 
studies claim that altered nuclear shape associates with chromatin 
reorganization and genomic instability, thereby affecting gene expression and 
cancer progression (He et al., 2008; Oberdoerffer and Sinclair, 2007). In 
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addition, others suggest that altered nuclear shape contributes to cancer 
metastases by reducing nuclear stiffness, which enables cancer cells to 
penetrate the tissues (Dahl et al., 2008; Webster et al., 2009). In respect to the 
cause of altered nuclear, aberrant expression and architecture of nuclear 
lamina are considered as the principle determinants of nuclear shape alteration 
(Goldman et al., 2002). 
1.3.2 Changes in nuclear matrix in cancer cells 
Nuclear matrix, a filamentous protein network in nucleoplasm, functions as 
skeleton to provide the framework for maintaining the overall size, shape and 
spatial arrangements of the nucleus. Moreover, nuclear matrix acts as scaffold 
to support diverse biochemical processes including, transcription, RNA splicing, 
DNA replication and so on. As a nuclear ribonucleoprotein network, nuclear 
matrix is composed of more than 200 nuclear matrix proteins including lamins, 
nuclear mitotic apparatus protein (NUMA), B23, hnRNP and so forth (Fey et al., 
1986; Mancini et al., 1996; Mattern et al., 1996; Zink et al., 2004). During cancer 
progression, the protein composition of nuclear matrix is changed. For instance, 
p114, which binds to the matrix attachment region (MAR) of DNA sequence, is 
detected specifically in human breast cancer, but not in normal breast tissues. 
Therefore, it is proposed to be a reliable diagnostic marker for breast cancer 
(Yanagisawa et al., 1996). In addition, some other nuclear matrix proteins are 
also specifically found in certain types of cancer tissues, such as PC1 in 
prostate tumor (Partin et al., 1997), a fusion protein between nuclear matrix 
protein NUMA and retinoic acid receptor-α (RARα) in acute promyelocytic 
leukemia (Sukhai et al., 2004) as well as BLCA-4 in bladder cancer (Konety et 
al., 2000). 
1.3.3 Alteration of nucleoli and perinucleolar compartment (PNC) 
Alteration of nucleolus is also frequently observed in cancer cell. Cancer 
nucleoli are significantly enlarged in Hodgkin’ disease and large cell carcinoma, 
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and has developed as a key diagnostic trait (Frost, 1986; Zink et al., 2004). At 
the periphery of the nucleolus, there is an irregularly shaped dynamic structure 
physically associated with nucleolus called perinucleolar compartment (PNC), 
which is enriched with RNA-binding proteins and short RNAs transcribed by 
RNA polymerase III (Huang et al., 1997; Pollock and Huang, 2010). PNC 
specifically exists in cancer cells but is rarely present in normal cells, therefore 
PNC is suggested as potential prognostic marker for cancer (Huang et al., 1997; 
Kamath et al., 2005; Norton et al., 2008). Furthermore, the presence of PNC 
widely correlates with metastatic capacity of various human cancers, including 
prostate cancer (Norton et al., 2008; Pettaway et al., 1996), colorectal cancer 
(Norton et al., 2008) and breast cancer (Samant et al., 2000). 
1.3.4 Promyelocytic leukemia (PML) bodies 
Promyelocytic leukemia (PML) nuclear body is a nuclear matrix associated 
multiprotein complex. These small structures of 0.2–1 μm in diameter exist in 
the nuclei of most cells with a number of 10-30 per nucleus (Boisvert et al., 
2000; Zink et al., 2004). PML bodies are assembled by tumor suppressor PML 
protein together with dozens of other proteins, such as retinoblastoma protein 
(Rb) and p53 (Zhong et al., 2000). It has been shown that PML bodies are the 
sites of p53 post-translational modification (Bernardi and Pandolfi, 2003; Fogal 
et al., 2000; Pearson et al., 2000), and PML bodies play key roles in both p53-
dependent and –independent apoptosis (Bernardi and Pandolfi, 2003; Wang et 
al., 1998). Moreover, PML bodies also play important roles in genomic stability 
and DNA repair (Bernardi and Pandolfi, 2003). Reduction or depletion of PML 
level is observed in several types of human cancers, including prostate, colon, 
breast, lung cancer and lymphomas (Chan et al., 1998; Gurrieri et al., 2004; 
Zhang et al., 2000). In addition, PML depletion is also associated with malignant 
invasion and progression of prostate cancer and breast cancer (Koken et al., 
1995). 
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1.3.5 Changes in chromatin organization 
Alterations in chromatin organization are another important features of 
malignant transformation. It has been widely shown that individual 
chromosomes occupy discrete nuclear regions, called chromosome territories 
(CTs). Furthermore, CTs display a radial positioning, with gene-poor CTs which 
usually present more close to nuclear periphery, whereas gene-rich CTs are 
nearer to the nuclear center (Boyle et al., 2001; Croft et al., 1999; Zink et al., 
2004). In the nuclei of cancer cells, the radial chromatin order appears to be 
partially lost (Cremer et al., 2003).  
The most well-investigated chromosomal aberration in cancer cells is 
chromosomal translocation, which has been applied as an important diagnostic 
trait (Zink et al., 2004). For instance, t (14; 18) (q32; q21) translocation is an 
important diagnostic marker for follicular lymphomas. Moreover, t (11; 14) (q13; 
q32) translocation is a maker of mantle-cell lymphoma (1997; Zink et al., 2004). 
In addition, changes in chromatin texture, caused by either chromatin 
condensation or decondensation, are also frequent observed in cancer cells, 
and suggested to be of diagnostic significance (Frost, 1986; Lukasova et al., 
2004). The easiest observations of chromatin texture alterations are chromatin 
coarsening and exaggerative open chromatin (Zink et al., 2004). Activation of 
HRAS oncogene is one of the causes for chromatin coarsening, which leads to 
heterochromatin aggregation and correlates with metastatic potential of cancer 
cells (Fischer et al., 1998). In addition, exaggerated open chromatins, resulted 
from loss of heterochromatin aggregates, also frequently present in various 
types of cancer cells (Frost, 1986).  
1.4 Nuclear envelope and nuclear lamins 
1.4.1 Structure and components of the nuclear envelope 
Nuclear envelope is composed of inner and outer nuclear membranes, nuclear 
lamina and nuclear pore complexes (NPCs). It plays an essential role in 
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separating the contents of the nucleus from the cytoplasm, providing the 
structural framework of the nucleus and maintaining the nuclear structure 
(Chow et al., 2012; Coutinho et al., 2009) (Figure 6).  
The outer nuclear membrane is continuous with the membrane of the rough 
endoplasmic reticulum (ER) with numerous ribosomes attached to the surface. 
Moreover, the perinuclear space between the inner and outer nuclear 
membranes is also directly connected with the lumen of the endoplasmic 
reticulum. In contrast, the inner nuclear membrane associates with a variety of 
nuclear specific proteins. The outer and inner nuclear membranes are fused 
into a highly curved membrane at the sites of NPCs, which are composed of 
approximately 30 different proteins, termed nucleoporins (Doucet and Hetzer, 
2010). NPCs act as selective channels that function together with soluble 
receptors to guide exchange of molecules (including proteins and RNA) 
between the nucleus and cytoplasm. The selective proteins and RNA trafficking 
mediated by NPCs are essential to the establishment of inner nuclear 
composition and regulation of gene expression, and also play a role in 
regulating cancer progression and metastasis (Chow et al., 2012; Strambio-De-
 
Figure 6. Structure of nuclear envelope (Coutinho et al., 2009). 
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Castillia et al., 2010; Wente and Rout, 2010). For instance, nucleoporin 
NUP155 was shown to interact with HDAC4 and enhance its inhibitory effect 
on the expression of target genes (Kehat et al., 2011). Furthermore, 
nucleocytoplasmic shuttling of Smad2, mediated by nucleoporins NUP214 and 
NUP153, is of critical importance in regulation of gene expression mediated by 
TGFß/SMAD signaling pathway (Xu et al., 2002). Besides, NUP153 also 
facilitates nuclear translocation of activated ERK1-ERK2 by direct interaction 
(Shindo et al., 2016). Moreover, depletion of nucleoporin NUP358 increases the 
cAMP-mediated cell adhesion in ovarian cancer cells (Gloerich et al., 2011). In 
addition, overexpression of nucleoporin NUP88 is widely observed in various 
cancers, and is considered as a cancer biomarker because of its association 
with aggressive cancer phenotype and poor prognosis (Agudo et al., 2004; 
Martinez et al., 1999; Zhang et al., 2007).  
1.4.2 Nuclear lamins 
The structural support to the nucleus is provided by fibrous meshwork of 
intermediate filaments which locate underlying the inner nuclear membrane, 
called nuclear lamina. The structural elements of nuclear lamina are lamins, 
which form polymers to constitute nuclear lamina. Nuclear lamins are 
subdivided into two different types, A- and B- type, based on their structural and 
protein features, expression pattern as well as biochemical and dynamic 
properties (Dechat et al., 2010; Dittmer and Misteli, 2011). A- type lamins are 
made up of two major isoforms, lamin A and lamin C, which result from 
alternative splicing of LMNA gene (Lin and Worman, 1993). In contrast, lamin 
B1 and lamin B2, which are the two main B- type lamins, are encoded by 
LMNB1 gene and LMNB2 gene, respectively (Peter et al., 1989; Vorburger et 
al., 1989). As illustrated in Figure 7, the protein structure of these two types of 
lamins generally resemble in the N-terminal head, central α-helical rod domain 
as well as C-terminal tail containing immunoglobulin domain and a conserved 
CAAX box (Dittmer and Misteli, 2011), which is the one responsible of nuclear 
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localization of lamins and establishment of protein-protein interactions 
(Kalinowski et al., 2013; Rusinol and Sinensky, 2006). 
In mammals, B-type lamins are constitutively expressed in all somatic cells, 
whereas A-type lamins are developmentally regulated and expressed in a 
tissue- and cell type-specific manner (Dechat et al., 2010; Dittmer and Misteli, 
2011). For instance, A-type lamins are absent in most neural and 
neuroendocrine cells as well as hematopoietic cells (Broers et al., 1997; Rober 
et al., 1990).  
It is widely acknowledged that A- and B-type lamins form separate filamentous 
networks and both networks overlap and interact with each other (Dechat et al., 
2010). In addition, rising evidences show that both types of lamin structures 
appear to compensate each other. For example, depletion of lamin B1 in Hela 
cells enhances the mesh size of A-type lamins network (Shimi et al., 2008). In 
consistence, another study also shows an enlarged A-type lamins meshwork 
after mutating lamin B1 (Vergnes et al., 2004).  
In respect to their subnuclear localization, although the majority of lamins are 
 
Figure 7. Protein structure of nuclear lamins (Dittmer and Misteli, 2011). 
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present in the nuclear periphery, some of them locate within the nucleoplasm 
(Dittmer and Misteli, 2011; Hozak et al., 1995). Nuclear peripheral lamins, which 
are integrated into the nuclear lamina, are relatively stable. In contrast, the 
nucleoplasmic A-type lamins are thought to be more dynamic and mobile. B-
type lamins in the nucleoplasm appear to be static and immobile (Broers et al., 
1999; Dechat et al., 2008; Moir et al., 2000b; Shimi et al., 2008). 
1.4.3 Function of nuclear lamins 
1.4.3.1 The role of lamins in regulating nuclear shape and mechanical 
properties 
Lamins are of critical importance to regulate nuclear shape and mechanical 
stability. Two independent studies have shown nuclear deformation in mouse 
embryonic fibroblasts (MEFs) isolated from Lmna-/- mice (Houben et al., 2007; 
Lammerding et al., 2004). Similar observation was also made by another study 
showing that loss of A-type lamins results in nuclear deformation in both human 
ES cells and epithelial cells (Pajerowski et al., 2007). The deformed nuclei 
caused by lamin A/C depletion are more fragile and show decreased 
mechanical stiffness compared with Lmna +/+ nuclei (Broers et al., 2004). 
Besides, mutation of A-type lamins also leads to irregular nuclei (Bechert et al., 
2003; Favreau et al., 2003; Vigouroux et al., 2001). In addition to A-type lamins, 
B-type lamins also form stiff meshwork which provides nuclei with structural 
strength enabling the nuclei to resist deformation (Panorchan et al., 2004a; 
Panorchan et al., 2004b). 
1.4.3.2 The role of lamins in DNA replication, damage and repair 
Several studies have shown the role of lamins in regulation of DNA replication. 
For example, lamins colocalize with replication-associated protein, such as 
proliferating cell nuclear antigen (PCNA), at DNA replication foci (Kennedy et 
al., 2000; Moir et al., 1994; Shumaker et al., 2008). Moreover, depletion (Meier 
et al., 1991; Newport et al., 1990) or dominant-negative mutations (Moir et al., 
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2000a; Shumaker et al., 2008; Spann et al., 1997) of B-type lamins disable the 
cells to replicate their DNA.  
In addition, lamins regulate DNA repair. It has been reported that cells 
expressing progerin, which is a truncated version of lamin A responsible of 
Hutchinson Gilford Progeria Syndrome (HGPS), have a high level of DNA 
damage by increasing the level of double-strand break marker γ-H2AX and 
inhibiting the recruitment of DNA repair factor p53-binding protein (53BP1) at 
the sites of DNA damage (Liu et al., 2005). Moreover, lamin A activates SIRT6 
in response to DNA damage, thereby facilitating SIRT6-mediated DNA repair 
(Ghosh et al., 2015). Furthermore, lamin B1 stabilizes RAD51, an essential key 
factor in the homologous recombination response taking place at the DNA 
double-strand breaks induced by ionizing radiation, in turn contributing to DNA 
repair (Liu et al., 2015a).  
1.4.3.3 The role of lamins in gene expression 
Increasing evidences support that lamins play key role in regulating gene 
expression by influencing transcription and a number of signaling pathway. On 
the one hand, lamins interact with various transcription factors and sequester 
them away from chromatin, thereby repressing the transcription of their target 
genes (Heessen and Fornerod, 2007). For example, lamin B1 associates with 
transcription factor Oct-1 at the nuclear periphery, thereby preventing Oct-1 
from activating the transcription of its target genes (Malhas et al., 2009). 
Furthermore, the sequestration of c-Fos at the nuclear envelope through direct 
interaction with lamin A/C was shown to suppress the DNA-binding thus the 
transcriptional activity of Activating Protein 1 (AP-1) (Ivorra et al., 2006). On the 
other hand, lamins also act as platforms for signaling molecules. For instance, 
A-type lamins facilitate dephosphorylation of pRb by recruiting nuclear 
phosphatase PP2A, thereby restoring the stability of pRb (Van Berlo et al., 
2005). Moreover, lamins influence wnt and TGFβ signaling pathway(Liu et al., 
2003; Vaughan et al., 2001) by interacting with emerin.  
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Additionally, lamins regulate gene expression by affecting RNA polymerase II 
activity. Downregulation of lamin B1 in Hela cells leads to inhibition of RNA 
polymerase II activity, thereby repressing the RNA synthesis (Tang et al., 2008). 
Besides, disrupting the lamin organization with dominant negative A-type 
lamins also represses RNA polymerase II activity (Spann et al., 2002). 
1.4.3.4 The role of lamins in epigenetic regulation 
Lamins play a crucial role on an epigenetic level by modifying chromatin 
structure, in turn influencing gene expression. Nuclear lamins are thought to be 
global regulators of chromatin via directly tethering heterochromatin to nuclear 
envelope. Depleting or mutating nuclear lamins results in loss of peripheral 
heterochromatin (Galiova et al., 2008; Nikolova et al., 2004; Shimi et al., 2008; 
Sullivan et al., 1999). These lamin-associated changes in heterochromatic 
organization are reflected by alterations in histone modification, including 
reduced levels of heterochromatin markers histone H3 lysine 9 trimethylation 
(H3K9me3), histone H3 lysine 27 trimethylation (H3K27me3) as well as 
elevated level of histone H4 lysine 20 trimethylation (H4K20me3) (Scaffidi and 
Misteli, 2006; Shimi et al., 2008; Shumaker et al., 2006). Furthermore, ectopical 
overexpression of lamins in myoblasts leads to alteration of chromatin 
organization along with enhanced level of H3K4me3, a marker of transcriptional 
activation (Hakelien et al., 2008).  
Human genome regions that interact with the nuclear lamins are referred to as 
lamina-associated domains (LADs) (Guelen et al., 2008). These domains are 
enriched with heterochromatic markers and labelled as gene-poor and 
transcriptionally repressive (Guelen et al., 2008; Peric-Hupkes et al., 2010). 
However, several other studies also claimed that lamins do not completely 
repress the expression of all the genes within LADs (Finlan et al., 2008; 
Kumaran and Spector, 2008; Reddy et al., 2008; Zheng et al., 2015). Moreover, 
Kim et al. demonstrated that B-type lamins binding profiles are associated with 
gene silencing but such interaction between B-type lamin and the silenced gene 
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is not necessarily required in mouse embryonic stem cells and differentiated 
trophectoderm cells (Kim et al., 2011). 
1.4.4 Nuclear lamins as cancer biomarkers 
A number of studies have been analyzed the expression of lamins in different 
cancers (Sakthivel and Sehgal, 2016). By examining a variety of lung cancer 
cell lines and specimens, Broers et al. revealed that B-type lamins is 
considerably downregulated in NSCLC, especially adenocarcinomas. In 
contrast, lamin A/C levels are significantly reduced in both SCLC cell lines and 
specimens (Broers et al., 1993). Another studies revealed that lamin A/C level 
is dramatically enhanced in oncogene v-rasH-expressing SCLC cell lines as 
well as v-rasH driven large cell carcinoma-like tumors. Importantly, the 
increased level of lamin A/C is positively associated with enhanced malignancy 
of lung cancer (Kaufmann et al., 1991). In consistence, another independent 
study also demonstrated that lamin A/C is overexpressed in adenocarcinoma 
cell line A549 in comparison with normal lung fibroblast cell line MRC-5 
(Rubporn et al., 2009).  
Moreover, high level of lamin A/C has been shown to correlate with poor 
prognosis and survival of colorectal cancer patients, and proposed to be a 
significant risk indicator for colorectal cancer (Willis et al., 2008). The interaction 
between lamin A/C and S100A6, an interacting partner of ß-catenin, is 
implicated in colorectal cancer development and progression (Kilanczyk et al., 
2012). However, paradoxically, another study showed that low level of lamin 
A/C associates with increased colon cancer recurrence (Belt et al., 2011).  
Lamin B1 upregulation is also observed in the prostate cancer and correlates 
with cancer differentiation level (Coradeghini et al., 2006). Moreover increased 
phosphorylation of B-type lamins in prostate cancer cell associates with altered 
structure of nuclear envelope, thus leading to changes in genes expression, 
which may ultimately contribute to a more aggressive cancer phenotype 
(Barboro et al., 2012; Sakthivel and Sehgal, 2016). Aside from B-type lamins, 
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A-type lamin levels have been shown to correlate with prostate cancer cell 
growth, invastion and migration via affecting PI3K/AKT/PTEN signaling 
pathway. Therefore, lamin A/C was prosposed to be a potential oncogenic 
biomarker and novel therapeutic target for prostate cancer (Kong et al., 2012). 
In support of this, another study revealed that the level of A-type lamins are 
positively correlated with Gleason score of prostate cancers. Therefore, lamin 
A was proposed to be a potential biomarker for discriminating between low- and 
high-grade prostate cancers (Skvortsov et al., 2011). 
Lamin A/C expression is reduced in keratinocytic tumors, especially in basal 
cell carcinoma and poorly differentiated cutaneous squamous cell carcinoma. 
In contrast, B-type lamins are downregulated in most well-differentiated 
cutaneous squamous cell carcinoma and keratoacanthomas. Therefore the 
levels of nuclear lamins are based on the differentiation level and 
transformation of skin, which may serve as a diagnostic trait of keratinocytic 
cancer (Oguchi et al., 2002). By correlating the proliferation rate of basal cell 
carcinomas cells with lamins expression, another study showed that loss of 
lamin A is associated with higher growth rate, whereas absence of lamin C is 
correlated with slow growth rate. It suggests that lamin A may negatively affect 
proliferation of basal cell carcinomas (Venables et al., 2001). 
By screening and correlating the mRNA level of both A- and B-type lamins in 
breast cancer and tumor adjacent non-cancerous tissues with 
clinicopathological data, Wazir et al. revealed that higher level of A-type lamins 
was correlated with better survival and clinical outcome. In contrast, reduced 
lamin B1 level associates with higher tumor grade and worse clinical outcome 
(Wazir et al., 2013). Moreover, loss of lamin A/C were also found in breast 
cancer cells along with aberrations in nuclear morphology and aneuploidy 
(Capo-chichi et al., 2011). 
In addition, Wong et al. revealed a significant upregulation of lamin B1 in 
hepatocellular carcinoma tissue and found a highly sensitive and specific way 
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to detect early hepatocellular carcinoma by checking the circulating lamin B1 
mRNA level in patients' blood samples (Wong and Luk, 2012). Similar study 
also showed that elevated lamin B1 level serves as an useful clinical marker for 
early detection of hepatocellular carcinoma, and positively correlates with tumor 
stages, tumor sizes, and number of nodules (Sun et al., 2010). 
The elevated lamin B1 level is correlated with poor prognosiss and increased 
metastatic incidence. Importantly, lamin B depletion reduces the proliferation, 
invasion and tumorigenicity of pancreatic cancer cells (Li et al., 2013). Moreover, 
decreased levels of both nuclear A- and B-type lamins are found and proposed 
to be potential biomarkers of early stages of gastrointestinal malignancy and 
gain of cytoplasmic lamin A/C level is observed and may serve as an indicator 
for more malignant stages of gastric cancer (Moss et al., 1999; Sakthivel and 
Sehgal, 2016). In addition, loss of A-type lamins enhances aggressiveness and 
drug resistance of human neuroblastoma (Maresca et al., 2012). 
 
Table 1. Role of nuclear lamins in different types of cancers 
Type of cancer alteration of 
lamins 
references 
Lung cancer Reduced A-type 
lamins level in 
SCLC 
Reduced B-type 
lamins level in 
NSCLC 
(Broers et al., 1993; Kaufmann et al., 
1991; Rubporn et al., 2009) 
Colorectal 
cancer 
Both elevated and 
reduced lamin A/C 
level 
(Belt et al., 2011; Kilanczyk et al., 
2012; Willis et al., 2008) 
Prostate cancer Elevated lamin A 
or lamin B1 level  
(Barboro et al., 2012; Coradeghini et 
al., 2006; Helfand et al., 2012; Kong 
et al., 2012; Skvortsov et al., 2011) 
Skin cancer Reduced A- or B-
type lamins 
(Oguchi et al., 2002; Venables et al., 
2001) 
Breast cancer Reduced A- or B-
type lamins 
(Capo-chichi et al., 2011; Wazir et al., 
2013) 
Hepatocellular 
cancer 
Elevated lamin B1 
level 
(Sun et al., 2010; Wong and Luk, 
2012) 
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Type of cancer alteration of 
lamins 
references 
Pancreatic 
cancer 
Elevated lamin B1 
level 
(Coradeghini et al., 2006; Li et al., 
2013) 
Gastric cancer Elevated  A- or 
B-type lamins 
(Moss et al., 1999) 
Neuroblastoma Reduced A-type 
lamins 
(Maresca et al., 2012) 
 
1.4.5 Nuclear lamins and cell migration 
Willis et al. observed an enhanced cell motility and invasiveness by ectopically 
expressing the lamin A in colorectal cancer cells. Moreover, they found that 
lamin A upregulates the T-plastin, an actin bundling protein, and lead to 
downregulation of E-cadherin, thereby facilitating cancer migration and 
invasion (Willis et al., 2008). However, in contradiction to this study, Lu et al. 
showed that increased level of lamin A/C impedes lung cancer cell motility by 
triggering actin remodeling (Lu et al., 2009).  
Furthermore, loss of A-type lamins has been shown to significantly induce the 
cell migration by reducing the nuclear lamina stiffness (Harada et al., 2014). In 
addition, lamin B1 facilitates the migration of epicardial cells by influencing the 
expression of genes related to cell adhesion and the extracellular matrix 
function (Tran et al., 2016).  
1.5 Epigenetic regulation of chromatin in cancer 
Alterations of chromatin organization and structure are frequently observed in 
human cancers, therefore emphases have been made on the role of chromatin 
remodeling and modification in driving cancer initiation and metastasis. It is 
widely known that genomic DNA wrap around a discrete protein octamer, made 
up of histone proteins H2A, H2B, H3 and H4, to form the nucleosome core 
particles, which are fundamental units of chromatin (Kornberg, 1974; Kornberg 
and Thomas, 1974). Additionally, nucleosomes are further folded into an 
ordered and compacted chromatin with the help of linker histone H1 and other 
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non-histone proteins (Laybourn and Kadonaga, 1991). The altered affinity 
between chromatin proteins and DNA as well as its resulting changes in 
chromatin architecture are of great importance for gene expression and other 
biological processes (Nair and Kumar, 2012). 
1.5.1 Chromatin remodeling in cancer 
Gene transcription requires not only the general transcription machinery and 
transcription factors but also the alteration of local structural dynamics of 
chromatin to enable the accesses of various factors to the genes (Khan et al., 
2015; Nair and Kumar, 2012). The compactness and accessibility of chromatin 
intimately associate with transcriptional activity. The less condensed chromatin 
is usually transcriptionally active, because the open structures facilitate the 
DNA accessibility to the transcription factors. Chromatin accessibility is 
regulated by ATP-dependent chromatin remodeling enzymes (chromatin 
remodelers), which are capable of modifying the chromatin architecture. To date, 
four families of chromatin remodelers have been well identified to alter 
chromatin structures by regulating the nucleosome mobility and positioning, 
including SWI/SNF (BAF), ISWI, CHD/NuRD and INO80 family (Langst and 
Manelyte, 2015). The role of chromatin remodelers in tumorigenesis and cancer 
metastasis has been intensively studied. For example, loss of BRM and BRG1, 
which are the subunits of SWI/SNF complex, were shown to facilitate cancer 
progression and metastasis by downregulating tumor suppressor genes and 
upregulating oncogenes and metastasis-promoting genes (Marquez-Vilendrer 
et al., 2016). Another study highlighted the role of Smarcd3/Baf60c, subunits of 
SWI/SNF family, in promoting the EMT of breast cancer cells by inducing the 
Wnt5a signaling pathway (Jordan et al., 2013). Moreover, metastatic tumor 
antigen 1 (MTA1), a core-subunit of NuRD complex, is upregulated in various 
human cancers and correlates with higher tumor grade, aggressiveness and 
poor prognosis (Lai and Wade, 2011). MTA1 is also implicated in several 
receptor tyrosine kinase-driven signaling pathway, such as HER2, estrogen 
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receptor (ER), thus influencing cancer progression and metastasis (Mazumdar 
et al., 2001; Molli et al., 2008).  
1.5.2 Posttranslational modifications of histones 
Posttranslational modifications of histones have been shown to modulate the 
overall affinity of nucleosome histones with DNA, alter nucleosome mobility, 
thus regulating chromatin relaxation and condensation (Nair and Kumar, 2012). 
The most well-known modifications of histones are methylation (me), 
acetylation (ac), ubiquitination (ub) as well as phosphorylation (ph) on certain 
amino acid (Berger, 2007; Kouzarides, 2007) (Figure 8). Histone methylation 
occurs at different degree depending on how many methyl groups are added 
onto the amino acid residue, including monomethyl (me), dimethyl (me2), 
trimethyl (me3). Furthermore, different sites of histone amino acid residues can 
be modified, such as histone H3 lysine (K) 4 (H3K4), H3K9, H3K27 or arginine 
(R) site 2 (H3R2), H3R8 and so on (Figure 8).  
Histone modifications are dictated by various enzymes including those which 
add a specific modification (referred to as “writers”) as well as enzymes which 
 
Figure 8. Posttranslational modification of histones. (www.thermofisher.com) 
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remove a specific modification (referred to as “eraser”) (Khan et al., 2015; Nair 
and Kumar, 2012). Histone acetyltransferases (HATs), histone 
methyltransferases (HMTs) and histone kinases are the examples of “writers” 
which add acetyl, methyl and phosphoryl groups, respectively. Whereas histone 
deacetylases (HDACs), histone demethylases (HDMs) and histone 
phosphatases are examples of “erasers” which remove acetyl, methyl and 
phosphoryl groups, respectively (Khan et al., 2015). 
1.5.3 Role of histone modification in gene expression 
Histone modifications influence gene expression in different ways (Table 2). For 
instance, histone acetylation associates with gene transcriptional activation 
(Hebbes et al., 1988; Verdin and Ott, 2015). Whereas histone methylation acts 
diversely as activator or repressor to gene expression depending on which 
amino acid residue is methylated and how many methyl groups are added onto 
the certain amino acid residue. For example, H3K4me3 and H3K36me3 
associate with transcriptional activation, whereas, H3K9me3, H3K27me3 and 
H4K20me3 are correlated with transcriptional repression (Barski et al., 2007; 
Zentner and Henikoff, 2013).  
Histone posttranslational modification influences the affinity between histone 
proteins and DNA by altering the steric effects and/or charge interactions, in 
turn resulting in the change of chromatin architecture. For instance, H4K16 
acetylation induces chromatin relaxation by impeding the formation of higher 
order chromatin structure thereby resulting in an open chromatin and facilitating 
transcriptional activation (Shogren-Knaak et al., 2006). On the other hand, 
histone modification alters the interaction between chromatin and chromatin 
binding proteins. For instance, H3K9me3 is recognized by heterochromatin 
protein 1 (HP1), which play a key role in inducing the formation of compact 
chromatin structure thereby reducing the accessibility of chromatin, which leads 
to transcriptional repression of target genes (Bannister et al., 2001). 
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1.5.4 Role of histone modification in cancer initiation and progression 
Various histone modifications have been proposed to be of diagnostic and 
prognostic value in human cancers and play a critical role in cancer progression 
and (Table 2). For instance, H3K9me3 silences several tumor suppressor 
genes by forming a heterochromatic structure, in turn impeding transcriptional 
initiation (Nguyen et al., 2002). Furthermore, the decreased level of H2B 
monoubiquitination (H2Bub) during breast cancer progression and metastasis 
is essential to estrogen receptor-α (ERα) regulated gene transcription in breast 
cancer cells by promoting transcriptional elongation of target genes and 
maintaining chromatin dynamics overall (Prenzel et al., 2011). In addition, loss 
of H3K27me3 is correlated with shorter overall survival time of cancer patients 
and is proposed to be a prognostic indicator for poor clinical outcome in patients 
with breast, ovarian, and pancreatic cancers (Wei et al., 2008). Besides, 
bivalent configuration of H3K4me3 and H3K27me3 is responsible for poising 
genes which are enriched in PI3K and TGFβ signaling pathways, thus leading 
to epigenetic silencing in ovarian cancer cells. Cancer specific bivalent marks 
are also proposed to potentially influence the cancer progression as well as the 
subsequent development of drug resistance (Chapman-Rothe et al., 2013).  
 
Table 2. The role of histone modifications in human cancer (adapted from Khan, S.A 
et al. 2015) (Khan et al., 2015).  
Modification Writers Erasers Function Cancer types 
H3K9ac GCN-5 SIRT-1; SIRT-6 Transcription 
initiation 
Lung, breast, varian 
H3K18ac CBP/p300  Transcription 
initiation and 
repression 
Lung, prostate, breast, 
esophagus 
H4K5ac CBP/P300; HAT1; 
TIP60; HB01 
 Transcription 
activation 
Lung 
H4K8ac TIP60; HB01  Transcription 
activation 
Lung 
H4K16ac TIP60; hMOF SIRT-1; SIRT-2 Transcription 
activation 
Colorectal, Lung, breast 
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Modification Writers Erasers Function Cancer types 
H3K4me SETD1A, 1B; 
ASH1L; MLL1, 2, 3, 
4; SETD7 
KDM1A; DM1B, 
5B; NO66 
Transcription 
activation 
Prostate, kidney 
H3K4me2 SETD1A, 1B; MLL1, 
2, 3, 4; SMYD3 
KDM1A, 1B, 5A, 
5B, 5C, 5D; NO66 
Transcription 
activation 
Prostate, lung, kidney, 
breast, pancreatic, liver 
H3K4me3 SETD1A, 1B; 
ASH1L; MLL1, 2, 3, 
4; SMYD3; PRMD9 
KDM2B, 5A, 5B, 
5C, 5D; NO66 
Transcription 
elongation 
Kidney, liver, prostate 
H3K9me SETDB1; G9a; 
EHMT1; PRDM2 
KDM3A, 3B; 
KDM3B; PHF8; 
JHDM1D 
Transcription 
initiation 
Myeloma, kidney, 
pancreas, prostate 
H3K9me2 SUV39H1; 
SUV39H2; 
SETDB1; G9a; 
EHMT1; PRDM2 
KDM3A, 3B, 4A, 
4B, 4C, 4D; 
PHF8; KDM1A; 
JHDM1D 
Transcription 
initiation and 
repression 
Prostate, pancreas 
H3K9me3 SUV39H1; 
SUV39H2; 
SETDB1; PRDM2 
KDM3B, 4A, 4B, 
4C, 4D 
Transcription 
initiation and 
repression 
Colorectal, myeloma, 
lung, prostate, breast, 
leukemia, stomach 
H3K27me EZH2; EZH1 JHDM1D Transcription 
activation 
Kidney 
H3K27me3 EZH2; EZH1 KDM6A; KDM6B Transcription 
repression 
Breast, pancreatic, 
ovarian, prostate, 
stomach, liver 
H4K20me3 SUV420H1; 
SUV420H2 
 Transcription 
repression 
Colorectal, myeloma, 
prostate, breast, lung, 
breast, lymphoma, 
colon, ovarian 
1.5.5 Role of histone modifications in EMT and cancer metastasis 
Histone modifications also play a key role in promoting EMT and cancer 
metastasis through a variety of mechanisms (Sun and Fang, 2016). 
1.5.5.1 Histone acetylation in EMT and cancer metastasis 
Histone acetylation has been shown to facilitate EMT and thus cancer 
metastasis by directly affecting the transcription of EMT markers or EMT 
transcription factors. For instance, H4K16 acetylation, mediated by histone 
acetyltransferase hMOF, is essential to maintain the expression of E-cadherin 
in breast cancer cells (Kapoor-Vazirani et al., 2008). Other than histone 
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acetyltransferase, histone deacetylases (HDACs) are recruited to E-cadherin 
promoter by EMT transcription factors, thus repressing the transcription of E-
cadherin gene, thereby triggering EMT and cancer metastasis. The recruitment 
of HDAC1/ 2 by Snail (Peinado et al., 2004) as well as the recruitment of 
HDAC1/2 (Aghdassi et al., 2012) or SIRT1 by Zeb1 (Byles et al., 2012) are 
responsible of the transcriptional repression of E-cadherin in cancer cells.  
1.5.5.2 Histone methylation in EMT and cancer metastasis 
In addition to acetylation, histone methylation also serves as modulator of EMT 
and cancer metastasis through affecting the expression of EMT related genes. 
For instance, DOT1L, which catalyzes H3K79me3, cooperates with the c-Myc-
p300 complex to transcriptionally activate Snail and Zeb1/2, in turn inhibiting 
the transcription of E-cadherin gene and thus facilitating EMT and metastasis 
(Cho et al., 2015). Furthermore, global elevation of H3K4me3 and H3K36me3 
was observed in TGFβ-mediated EMT, suggesting a genome-wide 
reorganization of these two permissive methylation marks (McDonald et al., 
2011). Moreover, histone arginine methyltransferase PRMT1 promotes EMT 
and metastasis by catalyzing asymmetric H4R3me2 at the promoter of ZEB1, 
thus transcriptionally activating ZEB1 (Gao et al., 2016). Besides, Snail recruits 
histone demethylase KDM1A to the promoter of CDH1 (E-cadherin gene), thus 
reducing the H3K4me2 levels, thereby repressing the CDH1 transcription. In 
this way, loss of H3K4me2, mediated by KDM1A, is essential to Snail mediated 
EMT in breast cancer (Lin et al., 2010a). 
Aside from permissive histone methylation, the repressive ones also influence 
EMT and cancer metastasis in various ways. For instance, Snail recruits 
methyltransferase G9a (Dong et al., 2012; Liu et al., 2015b) or Suv39h1 (Dong 
et al., 2013) to CDH1 promoter, in turn catalyzing H3K9me3 and thus 
repressing the transcription of CDH1. Moreover, H3K27me3 is also a key 
regulator of EMT and cancer metastasis, its role will be discussed in detail in 
Chapter 1.5.7. In addition, the arginine methyltransferase PRMT5 is also 
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recruited by Snail to CDH1 promoter, thereby catalyzing symmetric H4R3me2 
and thus transcriptionally repressing E-cadherin expression (Hou et al., 2008). 
Furthermore, in breast cancer cells, arginine methyltransferase PRMT7 forms 
a complex with YY1 and HDAC3 and is recruited to CDH1 promoter thus 
silencing the gene expression of E-cadherin by inducing H4R3me2 and histone 
deacetylation (Yao et al., 2014). 
1.5.5.3 Coordinated histone modification in EMT and cancer metastasis 
Numerous studies have revealed that multiple histone modifiers form 
complexes to collaboratively regulate transcription of EMT related gene 
(Suganuma and Workman, 2008; Sun and Fang, 2016) (Figure 9). For example, 
Zeb1/2 bind to CDH1 promoter, and recruit HDAC1/2 and G9a/GLP. HDAC1/2 
and G9a/GLP trigger H3K9 deacetylation and H3K9 methylation respectively. 
Meanwhile, LSD1 is also recruited by Zeb1/2, in turn demethylating H3K4me1/2 
and impeding the H3K9 re-acetylation (Shi et al., 2004; Shi et al., 2003; Wang 
et al., 2001) (Figure 9a). H3K9 methylation recruits HP1 protein which induces 
a more closed and compact chromatin structure. HP1 further recruits DNA 
methyltransferase 1(DNMT1) for DNA methylation (Smallwood et al., 2007) 
(Figure 9b). Altogether, these different changes of histone modifications act to 
repress the transcription of E-cadherin, thereby inducing EMT and cancer 
metastasis. 
Moreover, other studies revealed that methyl-H3K9-binding protein MPP8 is 
recruited and bind to G9a/GLP or Suv39-induced methyl-H3K9 (Figure 9c). 
MMP8 recruits DNMT3A for CpG methylation and class III HDAC SIRT1 for 
H4K16 deacetylation, which act together to repress the transcription of E-
cadherin genes (Kokura et al., 2010; Sun et al., 2015) (Figure 9d).  
Additionally, Snail interacts with Sin3a and polycomb repressive complex 2 
(PRC2), which induce histone deacetylation and H3K27me3, respectively  
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 (Herranz et al., 2008; Peinado et al., 2004). In this way, E-cadherin gene is 
transcriptionally repressed. In addition, Snail also recruits G9a and SUV39H1 
at CDH1 promoter to catalyze H3K9me2 and H3K9me3, in turn impeding the 
 
Figure 9. Coordination between different EMT transcription factor and histone 
modifier in regulating transcription of EMT associated genes (from Sun L & Fang J. 
2016) (Sun and Fang, 2016). 
 
Introduction 
35 
 
transcription of CDH1 (Dong et al., 2013; Dong et al., 2012). DNMT1/3 is further 
recruited by both PRC2 and H3K9 methylation-associated HP1 to catalyze CpG 
methylation of CDH1 promoter (Dong et al., 2012; Herranz et al., 2008; Wong 
et al., 2011b) (Figure 9f). Besides, Snail also recruits LSD1 to demethylate 
H3K4 at the promoter of CDH1 for transcriptional repression (Lin et al., 2010b). 
All the modifications mentioned above are critical for Snail-dependent E-
cadherin silencing and induction of EMT (Figure 9e, f).  
Aside from Zeb and Snail, Twist also affects the histone code by interacting with 
various histone modifiers (Figure 9g, h). For instance, Twist has been shown to 
recruit NuRD complex to deacetylate H3K27 for transcriptional repression (Fu 
et al., 2011). Moreover, PRC1 and PRC2 are recruited by Twist, in turn 
repressing the E-cadherin transcription by catalyzing H3K27me3 at its promoter 
(Yang et al., 2010). Furthermore, Twist also interacts with histone 
methyltransferase SET8, which play a key role in repressing gene transcription 
by inducing H4K20me1. Intriguingly, apart from the repressive role of Twist in 
gene transcription, Twist also play a role in promoting EMT by activating the 
Wnt signaling pathway (Shi et al., 2014) (Figure 9h). It has been reported that 
the TIP60-mediated di-acetylation of Twist at K73/K76 as well as H4K5/K8 di-
acetylation activate the transcription of WNT5A by recruiting BRD4, P-TEFb 
and RNA polymerase II to the promoter of WNT5A gene. In this way, Twist 
functions as a supporter to promote EMT and tumorigenesis of breast cancer 
(Shi et al., 2014) (Figure 9h). 
1.5.6 The role of Polycomb group complexes and H3K27me3 in cancer 
initiation and progression 
H3K27me3 is mainly catalyzed by the polycomb repressive complex 2 (PRC2), 
therefore major focus has been put on the role of this complex, especially its 
catalytic subunit enhancer of zeste 1 and 2 (EZH1 and EZH2), in cancer 
progression and metastasis (Hock, 2012; Kim and Roberts, 2016; Koppens and 
van Lohuizen, 2016; Pasini and Di Croce, 2016).  
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PRC2 consists of four core subunits, including the methyltransferase EZH1 or 
EZH2, EED, SUZ12 and RBAP46/48 (Kim and Roberts, 2016). EZH1 and 2 are 
responsible of PRC2-mediated H3K27me3 (Margueron et al., 2008; Shen et al., 
2008), while its physical interaction with EED and SUZ12 is indispensable for 
stabilizing its catalytic activity (Cao and Zhang, 2004; Pasini et al., 2004). In 
addition to PRC2, PRC1 is another type of polycomb repressive complex, which 
is constituted by CBX, RING1B, HPH and BMI. PRC1 is recruited to H3K27me3 
sites through recognition by the CBX subunit, then catalyzes the 
monoubiquitination of H2A (H2Aub), which works together with H3K27me3 to 
induce chromatin compaction and repress gene expression (Min et al., 2003; 
Wang et al., 2004) (Figure 10).  
 
 
Figure 10. The components of polycomb repressive complexes (PRCs) and their 
enzymatic activities in regulating genes transcriptions (from Vissers JH et al. 2012) 
(Vissers et al., 2012). 
 
The role of PRC in cancer has been widely studied and appears to be context 
and cancer type- specific. On the one hand, PRC2 repress the expression of 
various tumor suppressor genes by catalyzing H3K27me3, which contributes 
to cancer progression. 
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In agreement with this, a number of studies revealed that EZH2 is 
overexpressed in various types of human cancers, and correlated with 
aggressive cases and cancer progression (Hock, 2012). Moreover, 
pharmacologically or genetically disrupting EZH2 is sufficient to impede the 
proliferation and survival of EZH2-expressing cancer cells (Tan et al., 2007; 
Wilson et al., 2010). Futhermore, the H3K27me3 demethylase JMJD3 (also 
known as KDM6B), is underexpressed in human cancers (Agger et al., 2009; 
Barradas et al., 2009). Moreover, EZH2-H3K27me3 facilitates cancer 
metastasis by transcriptionally repressing tumor suppressor gene DLC1 (Au et 
al., 2013). 
However, on the other hand, PRC2 also acts as tumor suppressor in various 
types of human cancers, by transcriptionally repressing several oncogenes. For 
example, loss of EZH2 in T-acute lymphoblastic leukemia (T-ALL) is correlated 
with aggressiveness (Simon et al., 2012) by derepressing the Notch signaling 
pathway (Ntziachristos et al., 2012). Furthermore, disruption of EZH2 was 
shown to trigger T-ALL (Simon et al., 2012). In addition, the increased level of 
JMJD3 in Hodgkin’s lymphoma and T-ALL was shown to derepress target 
oncogenes by reducing the H3K27me3 level, in turn facilitating pathogenesis 
(Anderton et al., 2011; Simon et al., 2012).  
1.5.7 The role of Polycomb group complexes and H3K27me3 in EMT and 
cancer metastasis 
In addition to its role in cancer formation and progression, PRC and PRC-
mediated H3K27me3 play important role in modulating EMT and cancer 
metastasis. Yu et al. revealed that EZH2 level is increased significantly and is 
accompanied with decreased E-cadherin level in lymph node metastatic breast 
cancer in comparison with primary tumors, suggesting a supporting role of 
PRC2 in EMT and metastasis (Yu et al., 2012). Moreover, EZH2 and EZH2-
mediated H3K27me3 are critical in Snail-mediated E-cadherin repression and 
EMT in pancreatic cancer (Herranz et al., 2008). Additionally, in gastric cancer 
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cells, PRC2 induces H3K27me3 at CDH1 promoters, thereby facilitating 
metastasis (Xia et al., 2015). Furthermore, the H3K4me3-to-H3K27me3 switch 
occurs at the promoters of various EMT markers, including E-cadherin. In 
contrast, the H3K27me3-to-H3K4me3 switch occurs at the promoter of 
upregulated mesenchymal markers, such as N-cadherin (Malouf et al., 2013).  
Apart from the promoting role of PRC and H3K27me3 in inducing EMT and 
cancer metastasis, several studies also highlighted a suppressive role of PRC 
and PRC-mediated H3K27me3 in EMT and cancer metastasis. Cardenas et al. 
revealed the decreased levels of EZH2 and H3K27me3 at the promoter of ZEB2 
genes in the context of TGFß-mediated EMT in ovarian cancer cells. It leads to 
transcriptional activation of ZEB2 gene, in turn reducing the E-cadherin level 
and triggering EMT and metastasis (Cardenas et al., 2016). Similarly, another 
study found that H3K27me3 presents at the promoter of SNAI1 gene, thus 
reducing the Snail expression and thereby impeding Snail-mediated EMT. In 
contrast, JMJD3 activates Snail expression by removing the H3K27me3 mark 
from the SNAI promoter, thereby facilitating EMT and cancer metastasis 
(Ramadoss et al., 2012). Consistently, H3K27me3 is also present at the 
promoter of SNAI2 gene and is responsible for the transcriptional silencing of 
SNAI2 gene. However, removing of H3K27me3 mark by JMJD3 increases the 
level of Slug and thereby triggering EMT and cancer metastasis (Li et al., 2015).  
Thus, the role of PRC2 and H3K27me3 appear to be highly context and cell-
type specific. 
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2. Objectives 
Lung cancer is the number one cause of cancer-related death worldwide. 
Therefore, improving diagnostic, prognostic and therapeutic efficiency of lung 
cancer is of utmost importance. Clarifying the molecular determinants and 
mechanisms driving lung cancer formation, development, malignancy and 
metastasis are of great benefit to the early detection, prognosis and therapeutic 
treatment of lung cancer.  
Lung cancer cells are characterized by alteration of nuclear morphology and 
structure. Nuclear lamins, the major determinant of nuclear structure, especially 
lamin A/C, have been proposed as a lung cancer marker by several studies. 
Besides, lamin B1 also contributes to nuclear stiffness and integrity (Panorchan 
et al., 2004a; Panorchan et al., 2004b) and loss of lamin B1 facilitates lung 
cancer migration and metastasis possibly through reducing nuclear stiffness 
(Harada et al., 2014). Indeed, previous study in our lab correlated the lower 
level of lamin B1 with higher lung cancer tumor grade and found that lamin B1 
depletion enhanced mouse lung epithelial cell migration.  
The objective of present study is to focus on the following aspects: 1. To 
determine the specific function of nuclear lamins in lung cancer initiation, 
development and metastasis; 2. To investigate the role of lamins on cell 
morphology, nuclear architecture and gene expression profiles; 3. To study the 
role of lamins in cell proliferation, migration and invasion as well as the 
underlying mechanism; 4. To study the role of nuclear lamins in regulating gene 
positioning and chromoatin decondensation.  
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3. Results 
3.1 Expression of lamins in lung cancer patients 
3.1.1 Lamin B1 levels are decreased in lung cancer specimens 
Previous studies in the group indicated that lower levels of lamin B1 were 
 
Figure 11. Lamin B1 shows decreased expression in lung cancer patients. 
Immunohistochemistry analysis of representative tissue samples from different 
types and grades of lung tumors specimens from a tissue microarray stained with 
two different anti-lamin B1 antibodies: (A) Sigma-Aldrich, HPA050524 (B) Santa 
Cruz, sc-6216. AD, adenocarcinoma; SCC, squamous cell carcinoma; SCLC, small 
cell lung cancer. Scale bars, 25 μm. 
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associated with higher grade, poorly differentiated adenocarcinoma and 
squamous cell carcinoma. In order to determine whether aberrant level of lamin 
B1 may contribute to lung cancer initiation, progression and metastasis, we 
performed immunohistochemistry (IHC) on a human lung cancer tissue 
microarray with two different lamin B1 specific antibodies. Interestingly, the 
results revealed significantly lower level of lamin B1 in small cell lung cancer 
(SCLC) as well as a progressive loss of lamin B1 expression in high-grade 
adenocarcinoma (AD), squamous cell carcinoma (SCC), which are 
prognostically worse in comparison to lower grade tumors (Figure 11 and Figure 
12). Grade I cancer cells expressed higher levels of lamin B1, evaluated by H-
score of IHC staining, whereas in grade II and especially in grade III tumors, 
much fewer cells expressed lamin B1, typically at substantially lower levels 
(Figure 12).  
 
Figure 12. Statistical analysis of relative intensity (H-score) of lamin B1 IHC staining 
using different anti-lamin B1 antibodies in lung tumors of different types and grades 
as well as normal lung tissue. (A) Sigma-Aldrich, HPA050524 (B) Santa Cruz, sc-
6216. n=70 AD (20 Grade 1, 30 Grade 2, 20 Grade 3); n=69 SCC (16 Grade 1, 33 
Grade 2, 20 Grade 3); n=22 SCLC and n=20 NL. NL, normal lung tissue; AD, 
adenocarcinoma; SCC, squamous cell carcinoma; SCLC, small cell lung cancer. **, 
p<0.01 vs. NL; ***, p<0.001 vs. NL; #, p<0.05; ##, p<0.01 
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3.1.2 Lamin A/C levels remain unchanged in NSCLC, but decreases in 
SCLC specimens  
 In contrast, lamin A/C IHC staining in human lung cancer tissue microarray 
 
Figure 13. Expression of lamin A/C in lung cancer patients. (A) 
Immunohistochemistry of representative tissue samples from different types and 
grades of lung tumors from a tissue microarray stained with an anti-lamin A/C 
antibody. Scale bars, 25 μm. NL, normal lung tissue; AD, adenocarcinoma; SCC, 
squamous cell carcinoma; SCLC, small cell lung cancer. (B) Relative staining 
intensity (H-Score) for lamin A/C in lung tumors of different types and grades. n=70 
for AD (n=20 Grade 1, n=30 Grade 2, n=20 Grade 3); n=69 for SCC (n=16 Grade 1, 
n=33 Grade 2, n=20 Grade 3), n=22 for SCLC and n=20 for NL. **p < 0.01.  
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with anti-lamin A/C antibody shows no differences in terms of lamin A 
expression between normal lung tissue and all subtypes and grades of NSCLC, 
except for a decrease in SCLC (Figure 13). These observations, in consistence 
with the previous study in our lab, suggest that the lower level of lamin B1 
expression associates with higher lung cancer grades.  
3.1.3 Cells in tumor microenvironment highly express lamin B1 
In contrast to the low lamin B1 levels in cancer cells, we observed that non-
cancerous cells in the tumor microenvironment express high levels of lamin B1. 
However, lamin A/C levels were high in cancer cells, whereas the non-
cancerous cells express no lamin A/C (Figure 14).  
Moreover, in Grade II and in particular in Grade III tumors we observed clusters 
of cells highly positive for lamin B1 and stained positive for the 
immune/inflammatory marker CD45 (Figure 15). Thus, lamin B1 levels are 
significantly reduced in tumor cells of lung cancer patients, but high in immune 
cells, which have been shown to exhibit stage-dependent accumulation in 
human lung tumors (Banat et al., 2015).  
 
 
Figure 14. Non-cancerous cells in tumor microenvironment express high level of 
lamin B1 but no lamin A/C. Immunohistochemistry of consecutive lung cancer tissue 
samples using anti-lamin B1 antibody (Sigma-Aldrich, HPA050524) and lamin A/C 
antibody, showing high levels of lamin A/C and low levels of lamin B1 in lung cancer 
cells (arrows). Stroma cells (arrowheads) show high levels of lamin B1 and no lamin 
A/C. Scale bars, 25 µm.   
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Figure 15. Lamin B1 is highly expressed in immune cells. Co-immunostaining with 
CD45 and lamin B1 antibodies of representative Grade III adenocarcinoma (AD) and 
Grade III squamous cell carcinoma (SCC) samples showing that cells highly positive 
for lamin B1 are CD45 positive immune/inflammatory cells. Scale bars, 50 μm. 
 
3.1.4 Lamin B1 expression is decreased in lung cancers cell lines 
Futhermore, the decrease of lamin B1 levels in lung cancer compared to non-
malignant lung cells/ tissues was confirmed by Western blot analysis of mouse 
lung epithelial (MLE12) cells and normal human bronchial epithelium B2B 
(BEAS-2B) cells, compared to the highly aggressive, metastatic mouse Lewis 
lung carcinoma (LLC1) cells, as well as H69 human small-cell lung cancer cells 
(Figure 16 A). Interestingly, LLC1 cells showed abnormal nuclear shape and 
lamin B1 localization in comparison to MLE12 cells (Figure 16 B). Together, 
these findings support the notion that loss of lamin B1 may play a role in 
promoting lung cancer initiation, progression and malignancy. 
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Figure 16. Lamin B1 levels are decreased in lung cancers cell lines. (A) Immunoblot 
analysis of total cell lysates of mouse lung epithelial (MLE12) cells, mouse Lewis 
lung carcinoma (LLC1), human bronchial epithelium B2B (BEAS-2B) and H69 
human small-cell lung cancer cells, showing decreased lamin B1 levels in mouse 
and human lung cancer cell lines. (B) Confocal images of immunostaining for lamin 
B1 in MLE12 and LLC1 cells. Scale bars, 5 µm. White arrows show nuclear blebs 
and local lamin B1 loss in LLC1 cells, whereas red arrows point to abnormalities in 
lamin B1 staining. To more clearly visualize the staining pattern in the LLC1 cells, 
which had a weaker lamin B1 signal, we acquired the LLC1 images with higher 
exposure compared to the MLE12 cells. 
 
3.2 Lamin B1 depletion promotes EMT, anchorage-independent 
growth, cell migration and invasion 
3.2.1 Loss of lamin B1 in mouse lung epithelial cells leads to EMT 
To further gain insight into the mechanism by which lamin B1 loss promotes 
cancer cells migration and metastasis, we depleted lamin B1 in mouse lung 
epithelial (MLE12) cells and the highly aggressive, metastatic Lewis lung 
carcinoma (LLC1) cells by lentivirally driven shRNA-mediated silencing (Figure 
17 A and B). In consistence with previous data in our group, we observed that 
control MLE12 cells maintained a rounded, epithelial appearance in culture, 
however lamin B1 knockdown MLE12 cells develop a spindle-shaped 
morphology (Figure 17 C), which resemble morphologically mesenchymal cells. 
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These dramatic changes of lamin B1 knockdown cells share morphological 
similarities to those occurring during EMT, which is a crucial event during tumor 
progression and metastasis.  
EMT is characterized by loss of epithelial markers and gain of mesenchymal 
markers, thus, in order to investigate if these is the case in lamin B1 knockdown 
cells, we checked the expression of several EMT makers in both control and 
lamin B1 knockdown MLE12 cells by immunofluorescent staining and western 
blotting analyses. As shown by both analyses, lamin B1 knockdown cells exhibit 
significant reduction of epithelial marker E-cadherin in comparison to control 
 
 
Figure 17. Loss of lamin B1 lead to morphological changes of MLE12 cells. (A) 
Immunoblot analysis of total cell lysates of MLE12 cells expressing control shRNA 
or shRNA against lamin B1 using lamin B1 and lamin A/C antibodies. α-Tubulin 
served as loading control. (B) qPCR analysis of Lmnb1 and Lmna expression in 
MLE12 expressing control shRNA or shRNA against lamin B1 (right panel) (n=6). 
(C) Representative microscopic images of control and lamin B1 knockdown MLE12 
cells, showing morphological changes after lamin B1 silencing. Scale bars, 25 µm. 
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cells (Figure 18). In addition, the level of mesenchymal markers, such as 
fibronectin, vimentin and N-cadherin, increase dramatically after lamin B1 
silencing (Figure 18). These findings demonstrate that loss of lamin B1 is 
capable of inducing EMT and thereby results in a dramatic morphological 
change of lamin B1-depleted cells. 
3.2.2 Lamin B1 depletion promotes cell migration and invasion  
 
Figure 18. Expression of EMT markers in control and lamin B1 knockdown MLE12 
cells analyzed by immunofluorescent stainings (A) and Western blot analyses (B). 
Scale bars, 20 µm. 
 
 
 
Figure 19. Boyden chamber migration (left and middle panel) and invasion (right 
panel) assay on control and lamin B1-silenced MLE12 (left panel) and LLC1 cells 
(middle and right panel). Data are shown by mean ± SEM. *, p < 0.05 vs control; ***, 
p < 0.001 vs control. 
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EMT associates with increased migratory and invasive abilities during cancer 
progression and metastasis, thus we evaluated the migratory and invasive 
capacities of control and lamin B1 knockdown MLE12 and LLC1 cells by 
performing the Boyden chamber-based migration and invasion assays. As 
expected, lamin B1-depleted cells possessed significantly higher migratory and 
invasive capacities in comparison with control cells (Figure 19).  
3.2.3 Lamin B1 depletion enhances cell anchorage-independent growth 
The role of lamin B1 in cell proliferation appears to be complex and cell type 
specific (Butin-Israeli et al., 2012). Thus, we next tested the role of lamin B1 
silencing on cell proliferation and anchorage-independent growth. Interestingly, 
while lamin B1 silencing led to decreased cell proliferation in 2D adherent 
monolayer cultures (Figure 20 A), the capacity of MLE12 cells to form colonies 
in soft agar as a measure of anchorage-independent growth, one of the 
 
Figure 20. Loss of lamin B1 hinders proliferation of MLE12 cells in 2D adherent 
monolayer cultures but promotes anchorage-independent growth. (A) MTT assay to 
determine the effect of lamin B1 loss on cell proliferation (n=8). (B) Soft agar assay 
to assess the anchorage independent cell growth of control and lamin B1 knockdown 
MLE12 cells. Higher magnifications (right panels) show the increased colony size 
upon lamin B1 loss (n=6). Scale bars of left panels, 4 mm; Scale bars of right panels, 
0.5 mm. (C) Quantification of the number of colonies per field in the soft agar assay. 
***, p < 0.001 vs control. 
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hallmarks of malignant transformation(Hanahan and Weinberg, 2011), was 
markedly increased after downregulation of lamin B1 (Figure 20 B). 
Furthermore, the individual colony size was increased by lamin B1 depletion 
(Figure 20 B). Taken together, these data suggest that loss of lamin B1 play a 
key role in promoting EMT, anchorage-independent growth, cell migration and 
invasion. 
3.3 Lamin B1 depletion leads to upregulation of migration-
related genes 
To further gain insights into the mechanisms mediating the role of lamin B1 in 
EMT and cell migration, we performed RNA-Seq from control and lamin B1-
depleted MLE12 cells. Consistent with a well-known repressive function of 
lamin B1 on gene expression (Reddy et al., 2008), we observed a significantly 
high number of upregulated genes after lamin B1 depletion (Figure 21). Only 
72 genes were downregulated in lamin B1 knockdown cells, whereas 169 
genes are found to be upregulated upon loss of lamin B1 with a Log2 Fold 
Change > 1. Importantly, among these upregulated genes, 24 genes are well-
annotated cancer related genes, which are widely implicated in cancer initiation, 
progression, development, migration, metastasis and cancer related pathway, 
by KEGG database (http://www.genome.jp/kegg/, genes are listed in Figure 21 
A and C). Furthermore, we performed a Gene Ontology (GO) analysis to get a 
better understanding of the functional characteristics and the potentially 
involved biological processes of the upregulated genes upon lamin B1 depletion.  
Intriguingly, output of the analysis revealed over-representation for GO terms 
linked to migration and related signaling among the genes upregulated upon 
lamin B1 knockdown (Figure 21 B), which supports our finding that lamin B1 
depletion play a key role in modulating cells migration by altering the expression 
of key molecules involved in cell migration and signal transduction. 
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Figure 21. Loss of lamin B1 leads to upregulation of genes link to migration and 
related signaling. (A) Heat-map representation of RNA-seq analysis of control 
and lamin B1 knockdown MLE12 cells, showing a large number of genes involved 
in cancer development among the genes upregulated upon lamin B1 loss of 
function. (B) GO terms enriched among genes upregulated upon lamin B1 
knockdown. (C) Volcano plot showing log2 fold change plotted against log10 
adjusted P value for lamin B1 knockdown versus control MLE12 samples. Red 
dots represent genes upregulated and blue dots represent genes downregulated 
(adjusted P<0.05, fold change ≤0.5, ≥2) upon lamin B1 loss of function. Genes 
involved in cell migration and signaling are indicated.  
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3.4 Upregulation of the RET plays a key role in mediating the 
EMT and malignant phenotype upon lamin B1 loss 
3.4.1 The receptor tyrosine kinase RET is upregulated upon lamin B1 
depletion 
Among all the upregulated genes upon lamin B1 depletion which are associated 
 
Figure 22. Expression of RET in control and lamin B1-depleted MLE12, LLC1, B2B 
and H69 cells. (A) qPCR validation of RET and Gfra1 upregulation upon lamin B1 
depletion in MLE12 cells. Western blot (B) analysis and immunefluorescent staining 
(C) of RET in control and lamin B1 knockdown MLE12 cells. Scale bars, 100 µm. (D-
F) Increased mRNA level of RET in lamin B1-silenced LLC1 (D), B2B (E) and H69 
(F) cells compared with control shown by qPCR analysis. (A, D-F): data are shown 
by mean ± SEM. *, p<0.05 vs. control; **, p<0.01 vs. control; ***, p<0.001 vs. control. 
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with cell migration, particularly interesting was the upregulation of RET 
(rearranged during transfection) proto-oncogene and its co-receptor Gfra1 
(GDNF family receptor alpha-1). First of all, we confirmed the increased 
expression of RET and Gfra1 in lamin B1-depleted MLE12 cells by qPCR, 
western blot and immunofluorescent staining analyses (Figure 22 A-C). In 
addition, similar results were also observed in lamin B1-silenced LLC1 cells in 
comparison to control (Figure 22 D) as well as in normal human lung bronchial 
epithelial cell line BEAS-2B (B2B, Figure 22 E) and human small cell lung 
cancer cell line NCI-H69 (H69, Figure 22 F) showing that loss of lamin B1 leads 
to significant increase of RET mRNA level. 
3.4.2 Targeting RET inhibits the migration and invasion of lamin B1-
depleted cells 
RET is a member of the receptor tyrosine kinase family that is activated by the 
glial‐derived neurotrophic factor (GDNF) family of ligands. These peptides bind 
the RET co-receptors from the GFRA family. Ligand binding leads to complex 
formation between RET and its ligand‐bound co‐receptors, resulting in kinase 
 
 
Figure 23. Boyden chamber migration (A and B) and invasion (C) assay with control, 
lamin B1 knockdown (Lmnb1 KD), RET knockdown (RET KD) and lamin B1/RET 
double knockdown MLE12 (A) and LLC1 (B and C) cells. Data are shown by mean 
± SEM. **, p < 0.01 
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activation and stimulation of downstream signaling pathways affecting cell 
proliferation and migration (Mulligan, 2014).  
To further investigate the role of RET upregulation in mediating EMT and the 
increased migration of lamin B1 knockdown cells, we knockdown RET in control 
and lamin B1-depleted MLE12 and LLC1 cells by lentivirally driven shRNA-
mediated silencing. Importantly, we observed that RET knockdown lead to a 
significant decrease in the cell migratory and invasive capacities of lamin B1-
depleted cells (Figure 23).  
Moreover, inhibitory targeting RET via treating the lamin B1-depleted MLE12, 
LLC1, B2B and H69 cells with RET selective inhibitor vandatanib also lead to a 
significant reduction of the migratory ability (Figure 24). 
These findings suggest that inhibition of RET can reverse the increased 
migratory and invasive abilities upon lamin B1 depletion which suggests that 
lamin B1 depletion modulates cancer cells migration and invasion in a RET-
dependent manner. In contrast to lamin B1 depletion, silencing of lamin A/C did 
not have any effect on RET expression and cell migration, suggesting a specific 
role of lamin B1 in regulating EMT in mouse lung epithelial cells (Figure 25).   
 
 
Figure 24. Boyden chamber migration assay with control, lamin B1 knockdown 
(Lmnb1 KD) MLE12 (A), LLC1 (B), B2B (C) and H69 (D) cells treated with DMSO or 
20 nM Vandetanib. Data are shown by mean ± SEM. *, p < 0.05; **, p < 0.01; ***, p 
< 0.001. 
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3.4.3 RET upregulation promotes lamin B1 depletion mediated EMT 
Considering the EMT phenotype of lamin B1-depleted cells, we assumed that 
upregulation of RET may also play a role in regulating lamin B1 depletion-
mediated EMT and may thereby facilitate cancer cell migration and metastasis. 
In order to corroborate the assumption, we checked the level of EMT markers 
 
Figure 25. Silencing lamin A/C did not affect RET expression and cell migration. (A) 
qPCR analysis of RET, Lmnb1, Lmna expression in MLE12 expressing control 
shRNA or shRNA against lamin A/C. (B) Boyden chamber migration assay with 
control and lamin A/C KD MLE12 cells, treated either with DMSO or with 20 nM 
vandetanib (n=4). 
 
 
 
Figure 26. Expression of EMT markers in control, lamin B1 knockdown (lamin B1 
KD), RET knockdown (RET KD) and lamin B1/RET double knockdown MLE12 cells 
shown by immunofluorescent stainings (A) and Western blot analysis (B). Scale 
bars, 20 µm. 
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in lamin B1 knockdown and lamin B1/RET double knockdown MLE12 cells to 
investigate the effect of RET loss on lamin B1 depletion-mediated EMT. 
Intriguingly, we observe a dramatic reduction of mesenchymal markers in lamin 
B1/RET double knockdown MLE12 cells in comparison to lamin B1 knockdown 
MLE12 cells (Figure 26), implying a functionally involvement of RET 
upregulation in lamin B1 depletion-mediated EMT process. 
Moreover, ectopic overexpression of RET in MLE12 cells also led to 
significantly increase the migratory ability and was dramatically reversed by 
RET inhibitor treatment (Figure 27A). Furthermore, the ectopic RET 
overexpression reduced the level of epithelial marker E-cadherin and at the 
same time induceed the expression of mesenchymal markers (Figure 27B). 
Taken together, these data suggest that RET is a key downstream target of 
lamin B1, which mediates EMT and the increased migratory and invasive 
phenotype upon lamin B1 loss.  
 
 
Figure 27. Effect of RET ectopic overexpression on cell migration and EMT. (A) 
Boyden chamber migration assay with control and RET-overexprssing MLE12 cells 
(RET OE) treated with DMSO or 20 nM Vandetanib. Data are shown by mean ± 
SEM. **, p < 0.01. (B) Expression of EMT markers in control and RET OE MLE12 
cells assessed by western blot analysis. 
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3.4.4 P38 MAPK signaling pathway is activated upon RET overexpression 
in lamin B1-depleted cells 
Several studies have uncovered a role of RET in stimulating numerous 
signaling pathways affecting cell migration, including p38, JNK and ERK. 
Therefore we investigated whether these pathways were affected in lamin B1 
depleted mouse lung epithelial cells. To this end, first we examined whether 
components of the MAPK signaling pathway are activated upon RET 
overexpression in lamin B1-depleted cells.  
Immunoblot analysis for activated phosphorylated p38 (p-p38), phosphorylated 
JNK1/2 (p-JNK1/2) and phosphorylated ERK1/2 (p- ERK1/2) revealed a 
marked increase of p-p38 level, indicating p38 activation, in lamin B1-depleted 
MLE12 cells. The levels of p-ERK1/2, indicating ERK1/2 activation, were not 
changed and p-JNK1/2, indicating JNK1/2 activation, was even decreased 
(Figure 28 A). Importantly, depletion of RET in lamin B1-silenced cells lead to a 
 
 
Figure 28. Role of RET upregulation in activating MAPK signaling pathway upon 
lamin B1 depletion(A) Western blot analyses for activated p38, JNK and ERK1/2 of 
control and lamin B1 knockdown MLE12 cells. (B) Western blot analyses for p38 
and activated phospho-p38 in control, lamin B1 KD, RET KD, lamin B1/RET double 
KD, RET overexpressed (OE) MLE12 cells. 
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significant decrease in p-p38 (Figure 28 B). In addition, the level of p-p38 in 
RET-overexpressing MLE12 cells is higher than the one in the control (Figure 
28 B).These data indicate that p38 as a downstream target of RET can be 
activated by RET upregulation. 
3.4.5 RET/p38 axis is responsible for the increased migratory phenotype 
upon lamin B1 loss 
In order to investigate the role of the RET/p38 axis in mediating the increased 
migratory and invasive phenotype upon lamin B1 loss, we made use of a p38 
 
Figure 29. Effect of p38 inhibition on the increased migratory ability upon lamin B1 
loss. Boyden chamber migration assay with control and Lmnb1 KD MLE12 (A), LLC1 
cells (B), B2B (C) and H69 (D) as well as control and RET overexpressed (OE) 
MLE12 (E) treated with DMSO or 30 μM SB202190. Data are shown by mean ± 
SEM. *, p < 0.05; **, p < 0.01; ***, p < 0.001 
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selective inhibitor SB202190. Interestingly, treatment of lamin B1-silenced 
MLE12, LLC1, B2B and H69 cells with SB202190 induced a dramatic decrease 
in the migratory capacity (Figure 29 A-D). Moreover, the high migratory ability 
of RET-overexpressing MLE12 cells is dramatically reduced by p38 inhibitor 
treatment (Figure 29 E). These data indicate that the activation of p38 signaling 
pathway is induced by RET upregulation upon lamin B1-depletion and plays a 
key role in cancer cell migration and metastasis. 
Taken together, these data suggest that activation of RET/p38 signaling is 
responsible for the high migratory phenotype of lamin B1-depleted lung 
epithelial cells. 
3.4.6 RET upregulation play a key role in promoting migration and 
metastasis of lamin B1-depleted cells in vivo 
Next, we further analyzed the role of RET in lamin B1 depletion-mediated 
cancer cell migration and metastasis by in vivo approaches. To this end, we 
examined the role of RET on metastatic dissemination of lamin B1-depleted 
lung epithelial cells by intravenously injecting the control, lamin B1 knockdown 
(Lmnb1 KD), RET knockdown (RET KD) and lamin B1/RET double knockdown 
LLC1 cells in C57BL/6 mice. After 20 days we dissected the lung of each mouse 
to analyze the size and to count the number of tumor nodules. Importantly, the 
results showed that the loss of lamin B1 induces cell metastatic ability and 
tumor growth, evident by the dramatic increase of the metastatic area, number 
of tumor nodules and tumor volume of mice injected with lamin B1 knockdown 
cells in comparison to control counterpart. These observations support our in 
vitro data showing that loss of lamin B1 facilitates the cancer cell migration 
(Figure 30). Furthermore, silencing of RET inhibited tumor growth and 
metastatic ability of lamin B1-depleted cells, evident by the significant decrease 
in terms of the metastatic area, number of tumor nodules and tumor volume of 
mice injected with lamin B1/RET double knockdown compared to lamin B1 
knockdown LLC1 cells (Figure 30).  
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Figure 30. Lamin B1 depletion promotes formation of metastatic tumor lesions 
through a RET dependent mechanism. (A-D) Control, lamin B1 KD, RET KD and 
lamin B1/RET double KD LLC1 cells were injected intravenously into the tail vein of 
C57BL/6 mice for 20 days (n=6 each). Mice were sacrificed and examined for tumor 
metastases in the lungs. Macroscopic appearance (A, upper panels) and H&E 
staining (A, lower panels) of representative lungs. (B-D) Quantification of the 
metastatic area (B), microscopic tumor volume (C) and metastatic nodules (D) of 
mice injected with control, lamin B1 KD, RET KD and lamin B1/RET double KD LLC1 
cells. 
 
Moreover, we also analyzed the role of RET and lamin B1 on tumor growth and 
spontaneous metastasis in vivo by subcutaneously injecting the control, lamin 
B1 knockdown, RET knockdown and lamin B1/RET double knockdown LLC1 
cells in C57BL/6 mice (Figure 31). Interestingly, the tumor volume of mice 
transplanted with lamin B1 silenced LLC1 cells was similar compared to 
controls at day 20 after injection, although subcutaneous tumors were  
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significantly larger in mice injected with lamin B1 knockdown LLC1 cells at day  
 
Figure 31. Lamin B1 knockdown promotes tumor growth and metastasis via a RET 
dependent mechanism. Control, lamin B1 KD, RET KD and lamin B1/RET double 
KD LLC1 cells were injected subcutaneously into the flanks of C57BL/6 mice for 20 
days (n=6). (A) Quantification of the macroscopic tumor volume at different days 
after injection. (B, upper panels) representative image of the mice at day 20 post-
injection. Mice were sacrificed and the subcutaneous tumors were removed (B, 
lower panels). (C and D) Spontaneous metastasis in lungs. H&E staining of 
representative lungs (C) and quantification of the number of metastatic nodules in 
the lungs (D) of mice injected with control, lamin B1 KD, RET KD and lamin B1/RET 
double KD LLC1 cells (n=6). Scale bars, 2 mm. (E) Co-staining with RET and lamin 
B1 antibodies of metastatic nodules in the lungs of mice injected with control or lamin 
B1 KD LLC1 cells. Scale bars, 10 µm. Data are mean ± SEM. *p< 0.05, **p< 0.01. 
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16 (Figure 31 A and B). In contrast, RET depletion in control and lamin B1 
knockdown cells resulted in significant decrease in tumor volume. Importantly, 
a much higher number of spontaneous metastases with larger tumor volume 
were found in the lungs of mice injected with lamin B1-depleted LLC1 cells 
compared to controls, whereas almost no metastasis was observed in mice 
injected with RET knockdown and lamin B1/RET double knockdown LLC1 
(Figure 31 C and D). Consistently with the RET upregulation upon lamin B1 
loss observed in cell culture studies, the metastatic nodules in the lungs of mice 
injected with lamin B1-depleted LLC1 showed high RET expression (Figure 31 
E). Taken together, these data indicate that loss of lamin B1 plays a key role in 
mediating the EMT and malignant phenotype in vivo via upregulation of the 
proto-oncogene RET. 
3.5 RET levels negatively correlate with lamin B1 levels in lung 
cancer patients 
3.5.1 The levels of RET are increased in lung cancer patients 
To address the clinical significance of our findings, we investigated whether 
there is a correlation between lamin B1 and RET levels in lung cancer patients. 
To this end, we first analyzed RET expression in a human lung tissue microarray 
by performing immunohistochemical staining with RET specific antibody. As it 
is shown in Figure 32, RET is almost undetectable in normal lung tissue, but is 
significantly upregulated in different types of lung cancer specimen (Figure 32).  
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3.5.2 RET levels negatively correlate with lamin B1 expression in lung 
cancer specimens 
Moreover, we correlated the H-score of RET staining and lamin B1 staining in 
each individual human specimens. Intriguingly, the RET H-score in the tumors  
Figure 32. RET levels are increased in lung cancer specimens in comparison to 
normal lung tissue. (A) Immunohistochemistry of representative tissue samples from 
different types and grades of lung tumors, from a tissue microarray, stained with an 
anti-RET antibody. AD, adenocarcinoma; SCC, squamous cell carcinoma; SCLC, 
small cell lung cancer. Scale bars, 25 μm. (B) Relative RET staining intensity (H-
Score) in lung tumors of different types and grades. n=70 AD (20 Grade 1, 30 Grade 
2, 20 Grade 3); n=69 SCC (16 Grade 1, 33 Grade 2, 20 Grade 3), n=22 SCLC and 
n=20 NL. ***p < 0.001 vs NL. #p < 0.05. 
Results 
63 
 
was found to significantly negatively correlates with the lamin B1 H-score with 
a Pearson correlation coefficient r = -0.632, supporting a link between lamin B1 
loss and RET upregulation in lung cancer patients (Figure 33 A). Furthermore, 
 
 
Figure 33. Lamin B1 and RET expression show inverse correlation in lung cancer 
patients. (A) Pearson correlation between the relative staining intensity for lamin B1 
and RET; r, Pearson correlation coefficient. (B) Co-immunostaining of representative 
adenocarcinoma and squamous cell carcinoma Grade 3 samples with RET and 
lamin B1 antibodies showing that cells highly positive for lamin B1 express low levels 
or RET and vice versa. Scale bar, 50 μm. 
 
Results 
64 
 
we also observed a mutually exclusive pattern of lamin B1 and RET staining in 
lung cancer specimens (Figure 33 B). These data suggest a clinical significance 
and therapeutical potential of lamin B1 depletion and the consequential RET 
upregulation. 
3.6 Lamin B1 recruits the EZH1/2 histone methyltransferase to 
silence RET expression 
3.6.1 RET gene locates in lamina-associated domain with its promoter 
highly enriched with H3K27me3 
It has been shown that genomic regions that interact with nuclear lamins are 
transcriptional repressed and enriched with repressive heterochromatin marks 
(van Steensel and Belmont, 2017). Therefore, we investigated whether Ret 
gene directly interacts with lamin B1. ChIP-qPCR analysis revealed that lamin 
 
 
Figure 34. RET locates in LADs. (A) ChIP-qPCR analysis of lamin B1 binding at the 
Ret promoter (n=4). Data are shown as mean ± SEM. **, p < 0.01. (B) Schematic 
representation of the RET gene and its localization in LADs (top). Genome tracks of 
H3K27me3 of human lung tissue, showing that the RET promoter is decorated with 
H3K27me3 mark.  
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B1 directly binds to Ret promoter in MLE12 cells (Figure 34 A) and this 
interaction was disrupted upon lamin B1 depletion. Similar to our finding in 
MLE12 cells, analysis of lamin B1 and H3K27me3 ChIP-seq data of human 
lung tissue (Shah et al., 2013; Thurman et al., 2012) revealed that RET gene is 
located in a large lamina-associated domain (LAD) and is decorated by 
H3K27me3 at its promoter (Figure 34 B), suggesting similar mechanism of RET 
regulation in humans. 
3.6.2 Lamin B1 depletion leads to repositioning of RET and Gfra1 genes 
A number of studies revealed that spatial positioning of genes at nuclear 
periphery play a repressive role in regulating gene expression (Finlan et al., 
 
Figure 35. Lamin B1 Loss alters gene positioning. Representative DNA FISH images 
of RET (A) and Gfra1 (C) genes (Red) in control or Lmnb1 KD MLE12 cells. Cell 
nuclei were labeled by DAPI. Scale bars are 2 μm. Quantification of distance of RET 
(B) and Gfra1 (D) genes to nuclear periphery in each individual nucleus of control or 
Lmnb1 KD MLE12 cells. (n=50) ***: p < 0.001. 
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2008; Reddy et al., 2008; van Steensel and Belmont, 2017). Dissociation 
between gene and nuclear lamina leads to repositioning of gene away from the 
nuclear periphery, thus activates gene expression (Poleshko et al., 2017). To 
gain further insights into the molecular mechanism mediating the role of lamin 
B1 in lung cancer development, metastasis and gene regulation we first 
analyzed the spatial gene positioning of the RET (Chr. 6) and its co-receptor 
Gfra1 gene loci (Chr. 19) in control and lamin B1-depleted MLE12 cells by 
fluorescence in situ hybridization (FISH) analysis. Intriguingly, we found that 
RET and Gfra1 locate at the nuclear periphery in control cells, whereas loss of 
lamin B1 leads to repositioning of RET and Gfra1 away from nuclear periphery 
(Figure 35). 
3.6.3  Loss of lamin B1 alters morphology and location of chromosome 6 
Furthermore, we observed differences in the distribution of differentially 
regulated genes among chromosomes (Figure 36 A), e.g. Chr.6, showed higher 
percentage of upregulated genes in comparison to the % of RefSeq genes at 
 
 
Figure 36. Lamin B1 loss affects morphology and location of Chr.6. (A) Distribution 
among chromosomes of differentially regulated genes upon lamin B1 loss of 
function. (B) FISH chromosome painting of chromosome 6 and chromosome 10 in 
control or Lmnb1 KD MLE12 cells. 
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this chromosome, and Chr.10 showed lower percentage (Figure 36 A). Thus, 
we investigated the morphology and location of Chr.6 and Chr. 10 by 
chromosome painting. In control MLE12 cells, Chr. 6 territories were found near 
the nuclear lamina and were compact, whereas in lamin B1-depleted cells the 
nuclear territories occupied by Chr.6 were larger and more centrally localized 
(Figure 36 B). In contrast, no major difference was observed for Chr.10 (Figure 
36 B). 
3.6.4 Lamin B1 depletion reduces the enrichment of repressive histone 
marks at the promoter of both RET and Gfra1 
 
 
 
 
 
Figure 37. Proximity 
ligation assay (PLA) 
using anti-lamin B1 
with either anti-
H3K27me3 or anti-
H3K9me3 antibodies. 
Scale bars, 10 μm. 
Based on previous studies which have shown the role of lamins in regulating 
transcription by recruiting chromatin modifiers and transcription factors, we 
analyzed chromatin structure of control and lamin B1-depleted MLE12 cells. In 
support of the previous studies showing that lamina-associated domains (LADs) 
tightly associate with heterochromatin and enriched with repressive histone 
marks such as H3K9me2, H3K9me3 and H3K27me3 (van Steensel and 
Belmont, 2017), we observed that lamin B1 closely associates with H3K27me3 
and H3K9me3 by proximity ligation assay (PLA, Figure 37).  
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Figure 38. ChIP-qPCR analysis of H3K27me3, H3K9me3 and H3K9me2 occupancy 
at the Ret (A) or Gfra1 (B) promoter (n=4). Data are shown as mean ± SEM. *, p < 
0.05. **, p < 0.01. ***, p < 0.001.  
 
 
 
 
 
 
 
 
Figure 39. Genome tracks of 
H3K27me3 ChIP-seq in 
control and lamin B1 KD 
MLE12 cells (n=2) showing 
decreased levels of 
H3K27me3 upon lamin B1 
loss.  
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Moreover, ChIP-qPCR analyses for H3K27me3, H3K9me3 and H3K9me2 in 
control and Lmnb1 KD cells reveal dramatically reduced enrichment of all these 
three repressive histone marks at the promoter of both Ret and Gfra1 gene 
upon lamin B1 depletion (Figure 38).  
Furthermore, genome wide ChIP-seq analysis for H3K27me3 confirmed the 
decreased levels of H3K27me3 at the Ret promoter in lamin B1-depleted lung  
epithelial cells (Figure 39). The Ret promoter is found in a broad H3K27me3 
chromatin domain, which showed a global decrease of H3K27me3 upon lamin  
B1 loss-of-function (Figure 39). 
3.6.5 Loss of lamin B1 activates RET transcription by increasing the 
binding of transcription factor Ascl1 at Ret promoter 
Importantly, we found a significantly increased binding of transcription factor 
Ascl1, which has been widely shown to directly activate RET transcription and 
play a critical role in lung cancer development (Augustyn et al., 2014; Kosari et 
al., 2014), at the Ret promoter as well as increased accumulation of RNA 
polymerase II (Pol II, Figure 40 A and B). 
 
 
 
 
 
Figure 40. Lamin B1 
depletion increases the 
binding of Ascl1 and Pol II at 
Ret promoter. ChIP-qPCR 
analysis of Ascl1 (A) and Pol 
II (B) binding at the Ret 
promoter (n=4). Data are 
shown as mean ± SEM. *, p 
< 0.05. **, p < 0.01. 
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3.6.6 Ascl1 does not promote Ret gene positioning 
Thus, we analyzed the role of Ascl1 on Ret gene positioning and expression in 
lamin B1-knockdown MLE12 cells. While FISH analyses revealed that RET is 
more centrally localized in both lamin B1-depleted and Ascl1/lamin B1 double 
knockdown cells (Figure 41 A), RET expression was significantly 
downregulated upon Ascl1 depletion in lamin B1-silenced cells (Figure 41 B), 
suggesting that not only lack of tethering to the nuclear periphery leads to Ascl1-
dependent Ret gene activation.  
3.6.7 Lamin B1 binds to EZH1/2 and recruits EZH1/2 to chromatin 
Extensive epigenetic studies have revealed that H3K27 methylation is 
catalyzed by the methyltransferases enhancer of zeste homologs 1 (EZH1) and 
2 (EZH2), which are the core catalytic subunits of polycomb repressive complex 
2 (PRC2) (Cao et al., 2002; Czermin et al., 2002). Therefore, we hypothesized 
that the expression of RET might be also regulated by EZH1 and EZH2. In order 
 
 
Figure 41. Ascl1 depletion in Lmnb1 KD cells reduces RET transcription without 
affecting the positioning of Ret gene. (A) Representative DNA FISH images of 
the Ret gene (red) in Lmnb1 KD or Lmnb1/ Ascl1 double KD MLE12 cells. Scale 
bars are 2 μm. (B) qPCR analysis of Ascl1 and RET expression in Lmnb1 KD or 
Lmnb1/ Ascl1 double KD MLE12 cells (n=6). Data are shown as mean ± SEM. 
***, p < 0.001. 
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to understand the role of these methyltransferases in regulating RET 
expression, we first analyzed their expression in lamin B1 knockdown MLE12 
cells by western blot. Interestingly, although the global nuclear levels of EZH1/2 
remained the same, significant lower level of EZH1/2 was found in the 
chromatin bound fraction of lamin B1-depleted cells (Figure 42 A). These data 
suggest that lamin B1 might bind and recruit EZH1/2 to chromatin, thereby 
facilitating EZH1/2-mediated H3K27me3. 
Indeed, nuclear matrix/intermediate filament preparations demonstrated that 
EZH factors are retained throughout the nuclear matrix preparations from which 
 
 
Figure 42. Lamin B1 recruits EZH1/2 to chromatin. (A) Western blot analysis of EZH1 
and EZH2 level in nuclear extracts (NE) and chromatin bound fraction (CBF) of 
control and lamin B1 knockdown (Lmnb1 KD) MLE12 cells. (B) Immunostainings for 
lamin B1, lamin A/C and EZH1 or EZH2 of in situ nuclear matrix preparations of 
control and lamin B1 KD MLE12 cells. DNA content was assessed by DAPI staining, 
confirming that all chromatin has been removed. Scale bars, 5 µm. (C) Co-
immunoprecipitation of extracts from control and lamin B1 KD cells using control, 
EZH1 or EZH2 antibodies and detected with anti-lamin B1 antibody. 
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all chromatin detectable by DAPI staining has been removed in control mouse 
lung epithelial cells, but lost upon lamin B1 depletion (Figure 42 B). Thus, EZH 
factors are associated with the nuclear matrix through lamin B1. Moreover, co-
immunoprecipitation revealed that lamin B1 binds specifically to EZH1 and 
EZH2 (Figure 42 C).  
3.6.8 Loss of lamin B1 leads to reduced enrichment of EZH1/2 at Ret 
promoter and global decrease of H3K27me3 
Consistent with these results, EZH1 and EZH2 were not recruited to the Ret 
promoter in lamin B1 knockdown cells, whereas in control cells we detected 
strong association of both EZH1 and EZH2 to the promoter region of Ret 
(Figure 43).  
Importantly, we observed a global decrease of H3K27me3 upon lamin B1 loss-
of-function, consistent with the global decrease of chromatin-bound EZH1/2 
(Figure 44 A and B).  
 
 
 
 
 
 
 
Figure 43. Lamin B1 loss reduces 
enrichment of EZH1/2 at Ret promoter. 
ChIP-qPCR analysis of EZH1 and EZH2 
binding to the Ret promoter (n=4). Data 
are shown as mean ± SEM. *, p < 0.05. 
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3.6.9 Targeting EZH1/2 increases RET expression and phenocopies the 
enhanced migratory phenotype of lamin B1-depleted cells 
Next, we analyzed whether inhibition of EZH1/2 would phenocopy the 
increased migratory phenotype of lamin B1-depleted cells. To this end, we 
started by checking the efficiency of EZH1/2 inhibitor (UNC1999) treatment. 
Western blot analysis showed a significant decrease of H3K27me3 levels in 
MLE12 cells upon treatment with UNC1999 (Figure 45 A). This observation was 
confirmed by H3K27me3 ChIP followed by real-time PCR using specific primers, 
showing a dramatic reduction of H3K27me3 enrichment at the Ret promoter 
(Figure 45 B). Moreover, the reduction of H3K27me3 occupancy at Ret 
promoter mediated by UNC1999 treatment led to an increase of RET 
expression (Figure 45 C). Importantly, the migration capacity of MLE12 cells 
was also increased by UNC1999 application and could be restored to control 
levels by treatment with the RET inhibitor, Vandetanib (Figure 45 D), suggesting 
that RET functions as a downstream target of EZH1/2 to regulate cell migration  
 
 
Figure 44. Lamin B1 leads to global decrease 
of H3K27me3. Average H3K27me3 ChIP-Seq 
tag intensities (A) and heatmap of tag densities 
in control and lamin B1 KD cells at all 
H3K27me3 peaks in MLE12 cells (B). 
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upon lamin B1 loss. 
To further dissect the role of EZH1 and EZH2 in RET regulation and cell 
migration, we knockdown EZH1 and EZH2 in MLE12 cells by lentivirus-driven 
shRNA-mediated silencing. Intriguingly, we observed highly increased RET 
 
 
Figure 45. Inhibition of EZH1/2 activates RET expression and phenocopies the 
increased migratory phenotype of lamin B1-depleted cells. (A) Western blot analysis 
of global H3 and H3K27me3 levels in acid extracts of MLE12 cells treated with 
DMSO or the EZH1/EZH2 inhibitor UNC1999 (1 μM) for 3 days. (B) ChIP-qPCR 
analysis of H3K27me3 at the Ret promoter in MLE12 cells treated with DMSO or 1 
μM UNC1999 (n=4). (C) Relative RET expression levels in MLE12 cells treated with 
DMSO or 1 μM UNC1999 (n=6). (D) Boyden chamber migration assay with MLE12 
cells treated with DMSO, 1 μM UNC1999 or 1 μM UNC1999 and 20 nM Vandetanib 
(n=4). (E and F) Relative RET expression level in EZH1 (E) and EZH2 (F) 
knockdown MLE12 cells (n=6). (G) Boyden chamber migration assay with control, 
Ezh1 and Ezh2. knockdown MLE12 cells treated with DMSO, 20 nM Vandetanib or 
with 30 µM SB202190 (n=4). Data are mean ± SEM. *p< 0.05, **p< 0.01, ***p < 
0.001 Ezh1 KD or Ezh2 KD vs control; ###p < 0.001, #p < 0.05 vs DMSO. 
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expression in EZH1 depleted MLE12 cells in comparison to control cells (Figure 
45 E). In contrast, EZH2 silencing only led to a moderate increase of RET 
expression (Figure 45 F). Likewise, EZH1 depletion tremendously induced 
migratory capacity of MLE12 cells (Figure 45 G). However, EZH2 merely 
resulted in a slight increase of cell migration (Figure 45 G). Similar to the 
EZH1/2 inhibitor studies, treatment with the RET inhibitor vandetanib 
dramatically reduced migration of both EZH1 and EZH2 knockdown cells to 
control levels (Figure 45 G). In addition, treatment with p38 inhibitor SB202190 
also significantly decreased the migratory ability of EZH1- and EZH2 -silenced 
cells, comparable to control cells (Figure 45 G). Taken together, these data 
suggest that EZH1, instead of EZH2, play a more prominent role in mediating 
the malignant phenotype of lung epithelial cells with decreased lamin B1 levels.  
3.6.10 Depletion or inhibition of EZH1/2 does not affect the positioning of 
Ret gene 
 
Figure 46. EZH1/2 depletion or inhibition has no effect on the localization of Ret 
gene. Representative DNA FISH images of Ret gene loci (red) in control, EZH1 or 
EZH2 KD MLE12 cells (A) and MLE12 cells treated with DMSO or 1 μM UNC1999 
(B). Scale bars are 2 μm.  
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Next, we studied whether EZH1/2 depletion or inhibition affects Ret gene 
localization. We did not observe major changes in Ret positioning upon EZH1/2 
loss or inhibition (Figure 46 A and B), indicating that not only lack of tethering 
to the nuclear periphery but also loss of EZH1/2 activity is essential for Ret gene 
activation.  
3.6.11 Low levels of EZH1 are correlated with poorer prognosis of lung 
cancer patients 
We next analyzed whether there is a correlation of EZH1 level with survival of 
lung cancer patients using Kaplan Meier-plotter (publicly available). Consistent 
with the stronger effects observed on cell migration upon EZH1 depletion, lung 
cancer patients expressing low levels of EZH1 had a significantly poorer 
prognosis than patients with higher EZH1 expression (Figure 47).  
Taken together, these data support our finding that depletion of EZH1 and EZH2, 
especially EZH1, play a key role in upregulating RET in MLE12 cells upon lamin 
B1 depletion, thereby facilitating EMT, migration and metastasis. In respect to 
the inhibitory function of EZH1 and EZH2 in regulating RET expression, EZH1 
play a relatively dominant role in comparison to EZH2. 
 
 
 
 
Figure 47. Overall survival curves 
(Kaplan-Meier plot) of lung cancer 
patients (Gyorffy et al., 2013) 
expressing high vs low levels of 
EZH1. 
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3.7 Lamin B1 depletion induces aggressive lung tumor 
formation 
3.7.1 Loss of one Lmnb1 allele is sufficient to induce lung tumor 
formation 
In order to further corroborate the role of lamin B1 downregulation in facilitating 
lung cancer formation and development, we used genetic approach with mice 
carrying a Lmnb1 null allele (Figure 48 A). In consistence with published studies 
(Kim et al., 2011; Vergnes et al., 2004) and previous observations in our lab, 
Lmnb1-/- mice died at birth with profound lung abnormalities, whereas 
Lmnb1+/- mice, which showed lower lamin B1 protein levels (Figure 48 B), 
appeared normal at a young age although smaller than their littermates.  
 
Figure 48. (A) Schematic representation of the Lmnb1 genomic locus and Lmnb1 
targeting construct. (B) Western blot analysis of lysates from mouse embryonic 
fibroblasts derived from wild-type (WT) and Lmnb1+/- mice. 
 
 
Table 3. Incidence of spontaneous lung tumor formation in wild-type and Lmnb1+/- 
mice. 
 
WT Lmnb1 +/- 
6 months 1/15 (6.67%) 7/12 (58.3%) 
1.5 year 2/27 (7.4%) 21/23 (91.3%)  
Data are shown as number of tumor-bearing mice/ total number of mice. 
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Importantly, older mice had a very high incidence of spontaneous lung tumor 
formation. Seven out of 12 mice developed spontaneous tumors after 6 months, 
whereas 21 out of 23 mice showed tumors by 1.5 years of age (Figure 49, Table 
3).  
3.7.2 Most of the lung tumors induced by lamin B1 haploinsufficiency 
were histologically similar to small cell lung cancer 
To further evaluate the cancer type of the spontaneous pulmonary tumor in the 
 
 
 
Figure 49. Lamin B1 haploinsufficiency induces aggressive lung tumor formation 
with most of them histologically similar to small cell lung cancer. (A) Histological 
analysis of representative lung sections of wild-type and Lmnb1+/- mice at 1,5 year 
of age; tumors are indicated by arrows. Scale bars, 100 µm. (B) High magnification 
images of tumors with SCLC characteristics (left panel) and tumors with AD 
characteristics (right panel). Scale bars, 20 µm. (C) Immunohistochemical staining 
of tumors in lungs of Lmnb1+/- mice with pan-cytokeratin (PanCK), CD45, CGRP, 
Syp, Ki67 and PCNA. Scale bars, 100 µm.  
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Lmnb1+/- mice, we performed histological examination and IHC staining of WT  
and Lmnb1+/- lungs. We found that apart from a small fraction of tumors which 
exhibited morphological similarities to adenocarcinoma (Figure 49A panel 6, 
Figure 49B right panel), most of the tumors in Lmnb1+/- mice showed strikingly 
similar characteristics to small cell lung cancer (Figure 49A, panel 3-5, Figure 
49B, left panel). The cells in these tumors were small with scant cytoplasm and 
densely packed chromatin, which obscured the nucleoli (Figure 49B, left panel). 
Furthermore, these tumors express, on the one hand, a high level of pan-
cytokeratins (panCK), which marks epithelial tumors, and on the other hand, 
calcitonin gene-related peptide (CGRP) and synaptophysin (Syp), markers for 
small cell lung cancer of neuroendocrine origin (Meuwissen et al., 2003). 
Importantly, the lesions were negative for CD45, a marker for cells of 
haematopoietic origin (Figure 49 C), which ruled out the possibility of being 
lymphocytes. Additionally, immunostaining of Ki67 and PCNA indicates a high 
proliferative index within these lesions (Figure 49 C).  
Taken together, these data reveal that the lack of a single functional Lmnb1 
allele is sufficient to efficiently induce the formation of aggressive lung tumors, 
most of which display remarkable similarities to small cell lung cancer in human 
patients. 
3.7.3 Tumors were also found in the kidney and liver of Lmnb1+/- mice 
Analyses of other organs revealed tumors in the kidney and the liver. Similarly 
to the SCLC-like tumors in the lungs of the Lmnb1+/- mice (Figure 49), the cells 
in the tumor nodules in livers and kidneys were small with scant cytoplasm, 
expressed CGRP, Syp, panCK, but were negative for CD45 and were found 
close to blood vessels (Figure 50), suggesting that these might be 
extrapulmonary metastases rather than primary tumors in these organs. 
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3.7.4 Pulmonary tumors in Lmnb1+/- mice show RET upregulation, 
RET/p38 activation as well as reduced enrichment of H3K27me3 
and EZH1/2 at Ret promoter 
In our cell culture studies, we found that loss of lamin B1 leads to RET 
upregulation and activation, followed by activation of the p38 signaling pathway. 
Thus, we next examined whether the tumors developed in Lmnb1+/- mice 
express RET, p-RET and p-p38. Indeed IHC analysis revealed that the tumors 
developed in Lmnb1+/- mice expressed very high RET, activated RET (p-RET) 
levels and activated p-p38 levels (Figure 51), supporting a link between lamin 
B1 deficiency, RET upregulation and RET/p38 activation in a genetic model of 
lamin B1 loss of function.  
 
Figure 50. Immunohistochemical staining of representative metastatic tumors in 
lives and kidneys of Lmnb1+/- mice with anti-panCK, CGRP, Syp, CD45, Ki67 and 
PCNA antibodies. Scale bars: panel no. 2 and 4, 20 µm; the rest of panels, 100 µm 
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Next, we analyzed H3K27me3 levels and EZH1/2 recruitment to the RET locus 
in lungs of wild-type and Lmnb1+/- mice. Consistent with our cell culture studies, 
we observed a significant decrease in H3K27me3 levels and EZH1/2 
occupancy at the Ret promoter (Figure 52). 
 
 
 
Figure 51. Lamin B1 haploinsufficiency induces RET upregulation and RET/p38 
activation. Immunohistochemical staining of lungs of wild-type and Lmnb1+/- mice 
with RET, phospho-RET (p-RET Y1062) and phospho-p38 (p-p38 Thr180/Tyr182) 
antibody. Scale bars, 100 µm.  
 
 
 
Figure 52. Lamin B1 
haploinsufficiency decreases 
H3K27me3 levels and EZH1/2 
occupancy at the Ret promoter 
(A) ChIP-qPCR analysis of 
H3K27me3 at the Ret promoter 
in wild-type and Lmnb1+/- lungs 
(n=4). (B) ChIP-qPCR analysis 
of EZH1, EZH2 binding to the 
Ret promoter in wild-type and 
Lmnb1+/- lungs (n=4). 
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3.8 Model of the role of lamin B1 as a tumor suppressor in lung 
cancer development and metastasis 
In summary, our data demonstrate that loss of lamin B1 plays a key role in 
promoting lung cancer development and metastasis. We found that lamin B1 
levels were reduced in lung cancer patients. Lamin B1 silencing in lung 
epithelial cells promoted epithelial–mesenchymal transition, cell migration, 
tumor growth, and metastasis. Mechanistically, we show that lamin B1 recruits 
the EZH1/2 to alter the H3K27me3 landscape and repress genes involved in 
cell migration and signaling. In particular, epigenetic derepression of the RET 
proto-oncogene by loss of EZH1/2 recruitment, and activation of the RET/p38 
signaling axis, play a crucial role in mediating the malignant phenotype upon 
lamin B1 disruption. Importantly, loss of a single lamin B1 allele induced 
spontaneous lung tumor formation and RET activation. Thus, lamin B1 acts as 
a tumor suppressor in lung cancer, linking aberrant nuclear structure and 
 
 
Figure 53. Model of the role of lamin B1 as a tumor suppressor in lung cancer 
development. In lung epithelial cells lamin B1 recruits the EZH1/2 histone 
methyltransferase to silence the expression of the RET proto-oncogene. Upon lamin 
B1 loss, recruitment of EZH1/2 to the Ret promoter is abolished leading to increases 
of RET expression, RET/p38 activation, EMT and metastasis.  
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epigenetic patterning with malignancy (Figure 53). 
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4. Discussion 
4.1 Lamin B1 as a potential marker of lung cancer 
In the present study, we describe a crucial role of lamin B1 in lung cancer 
development and metastasis. Changes in the expression of lamins have been 
already linked to various tumor entities, however, the relationship appears to be 
complex and tumor type specific. Thus, while increased levels of lamins were 
reported in some cancers, such as hepatocellular carcinoma, colorectal and 
skin cancer (Marshall et al., 2010; Tilli et al., 2003; Willis et al., 2008), a 
reduction of lamins has been observed in others, including gastric and breast 
cancer as well as large B cell lymphoma (Agrelo et al., 2005; Capo-chichi et al., 
2011; Wu et al., 2009). In respect to lung cancer specimens, the expression of 
lamins shows discrepancy among different studies. For instance, Broers et al. 
revealed a dramatic reduction of lamin A/C levels in both SCLC cell lines and 
specimens (Broers et al., 1993). This finding is in line with our observation 
showing a decrease of lamin A/C levels in SCLC specimens. However, elevated 
lamin A/C levels were observed in SCLC specimens and were positively 
correlated with enhanced malignancy of lung cancer (Kaufmann et al., 1991). 
In our study, we found reduced lamin B1 levels in different types of lung cancer 
specimens in comparison to normal lung tissues. In consistence with our finding, 
Broers et al. showed that B-type lamins expression was negative in non-small 
cell lung cancer cell lines, especially in adenocarcinomas (Broers et al., 1993). 
Although irregular expression of lamins is universally found in different types of 
human cancer cell lines and specimens, little is known about the mechanistic 
role of aberrant lamins expression in cancer initiation, progression, 
development and metastasis.  
In addition, we observed that lower lamin B1 expression correlates with higher 
tumor grade in both adenocarcinoma and squamous cell carcinoma, 
suggesting that loss of lamin B1 associates with the progression and 
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malignancy of lung cancer. The role of lamin B1 in lung cancer initiation and 
progression were further corroborated by our finding that loss of a single lamin 
B1 functional allele is sufficient to dramatically elevate the occurrence of 
spontaneous pulmonary tumors in mice. Furthermore, the promoting role of 
lamin B1 in lung cancer development and progression is further supported by 
cell culture studies and intravenous/ subcutaneous injection of LLC1 and 
MLE12 cells.  
4.2 The role of lamin B1 in cell proliferation and tumor initiation  
The role of lamin B1 in cell proliferation is complex and cell type specific. 
Several studies have shown that lamin B1 depletion induces senescence and 
reduces proliferation in human embryonic fibroblasts (Shah et al., 2013; Shimi 
et al., 2011) and lead to an earlier onset of proliferative crisis in mouse 
embryonic fibroblasts (Vergnes et al., 2004). However, lamin B1 knockout 
embryonic stem cells do not show any obvious proliferation defects ( (Kim et 
al., 2011) and our own observations). Moreover, lamin B1/lamin B2 double 
knockout keratinocytes proliferate normally in cell culture (Yang et al., 2011). In 
addition, the role of lamin B1 in modulating cell growth and proliferation appears 
to be O2 concentration dependent. For instance, the lamin B1 depletion-induced 
proliferation defects in WI-38 human diploid fibroblasts can be rescued by 
growth under hypoxia (1.5% O2; (Shimi et al., 2011)), conditions which are 
characteristic of tumors and can even occur in normal tissues. 
It is noteworthy that all the experiments in the above-mentioned studies were 
carried out in 2D adherent monolayer cultures, which often do not properly 
reflect the growth and transformation potential of cells in vivo. The latter is more 
faithfully recapitulated by 3D culture conditions that do not depend on 
anchorage to plastic surfaces, such as colony formation assays in soft agar. 
Therefore, in our study, we assessed the role of lamin B1 silencing not only on 
cell proliferation in adherent monolayers (anchorage-dependent conditions) but 
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also on anchorage-independent growth in soft agar. We observed that lamin B1 
silencing led to decreased cell proliferation in monolayer cultures, which is 
consistent with some of the studies mentioned above. Importantly, however, the 
capacity of MLE12 cells to form colonies in soft agar as a measure of anchorage 
independent growth, one of the hallmarks of malignant transformation 
(Hanahan and Weinberg, 2011), was markedly increased by downregulation of 
lamin B1. Furthermore, the individual colony size was markedly increased by 
lamin B1 depletion. This is consistent with the pronounced differences in tumor 
growth and metastatic dissemination in vivo of lamin B1 knockdown MLE12 
cells compared to control cells. In support of our finding, discrepancy between 
anchorage-dependent and -independent growth has also been observed in 
other studies. For example, Rotem et al (Rotem et al., 2015) showed that 
anchorage-dependent growth of cells did not correlate to anchorage-
independent growth and that non-transformed cells grew faster than 
transformed cells in high-attachment conditions, in stark contrast to low-
attachment conditions. 
The potential mechanism by which lamin B1 depletion leads to lung cancer 
initiation still remains unknown. Studies found that lamin B1 depletion led to an 
increased accumulation of DNA damage and genomic instability (Butin-Israeli 
et al., 2015). Considering that DNA damage and genomic instability, together 
with the consequential mutations of genes, are widely regarded as a major 
cause of tumorigenesis (Hoeijmakers, 2009), loss of lamin B1 may lead to 
cancer initiation by inducing DNA damage and genomic instability. 
Several gene mutations have been shown to drive pulmonary tumorigenesis. 
For instance, gain-of-function mutations of EGFR, KRAS and RET are 
frequently observed in non-small cell lung cancer (Carper and Claudio, 2015). 
Loss of the tumor suppressors TP53 and RB1 is also shown to be obligatory in 
SCLC by another study (George et al., 2015). Therefore, to investigate the 
potential mutations caused by lamin B1 depletion-mediated DNA damage and 
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genomic instability may help to reveal the molecular mechanism of 
tumorigenesis upon lamin B1 loss of function. 
4.3 The role of lamin B1 in cancer cell migration and metastasis 
Loss of nuclear lamins is implicated in regulating cell motility and migration by 
reducing the nuclear lamina stiffness (Harada et al., 2014). Successful 
migration and metastasis requires cell to deform in order to squeeze through 
tiny space between endothelial barriers to intrastate or extravasate. Therefore, 
as the largest single organelle in every cell, nucleus should soften in this 
procedure. After metastasis, a stiff nucleus helps cell withstand the stress from 
the microenvironment. Lamin A was shown to effectively stiffen nuclei, thereby 
reduced lamin A level facilitates cell migration by decreasing the nuclear 
stiffness (Harada et al., 2014; Song et al., 2016). In addition, lamin B1 regulates 
the expression of genes responsible for cell adhesion and extracellular matrix 
function in epicardial cell (Tran et al., 2016), implying a potential role of lamin 
B1 in regulating epicardial cell migration. In consistence with a previous 
observation in our group, we found a strong increase in migratory and invasive 
capacities in lamin B1 knockdown MLE12 and LLC1 cells in comparison with 
their control counterpart, respectively. Importantly, silencing of lamin B1 in both 
cell types dramatically increased tumor growth and metastasis showing by mice 
model intravenously/subcutaneously injected with control and lamin B1 
depleted cells.  
Theoretically, lamin depletion may contribute to cell migration and metastasis 
by increasing the plasticity of nuclear shape, thus facilitating changes in cell 
form that are required for penetrating restricted spaces, in particular during 
intravasation of cancer cells from primary tumors into the vasculature and 
extravasation into metastatic sites (Denais et al., 2016; Friedl et al., 2011). 
However, RNA-seq analysis on control and lamin B1 knockdown cells revealed 
significant enrichment of differentially expressed genes linked to migration and 
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metastasis related signaling in the genes upregulated upon lamin B1 depletion, 
suggesting a direct role of lamin B1 in the regulation of cancer cell migration 
and metastasis at the gene expression level. On the other hand, the fact that 
lamin B1 depletion mainly upregulates migration and metastasis related genes, 
instead of the genes associated with other biological processes, suggesting that 
lamin B1 might not randomly bind to the genome in lung epithelial cells, but 
specifically interact with certain genome regions thereby specifically repress the 
transcription of genes involved in EMT and cell migration.  
Consistently, we observed a dramatic loss of cell-cell adhesion molecule E-
cadherin and changes in cell morphology in MLE12 cells upon lamin B1 
depletion. In contrast to the control cells which show cobblestone-like epithelial 
appearance, the lamin B1 KD MLE12 cells exhibit spindle-shaped morphology 
and increased expression of mesenchymal markers, suggesting that lamin B1-
depleted cells undergo EMT. Since EMT has been widely considered as a major 
contributor to cancer cell migration and metastasis (Heerboth et al., 2015; 
Kalluri and Weinberg, 2009), therefore lamin B1 depletion-mediated EMT 
phenotype may play an important role in facilitating the migration and 
metastasis of lamin B1 knockdown cells. Taken together, our study for the first 
time correlates loss of lamin B1 with EMT phenotype in cancer migration and 
metastasis. 
4.4 Loss of lamin B1 upregulates RET thereby triggering EMT 
and cancer cell migration and metastasis 
Nuclear lamins, including lamin B1, are in close association with 
heterochromatin, which is tightly packed and inaccessible to transcription 
factors. Therefore, genomic regions that are in close contact with the nuclear 
lamins, termed lamina-associated domains (LADs), are usually transcriptionally 
silenced (van Steensel and Belmont, 2017). In consistence with the repressive 
role of lamin B1 in transcription regulation, we observed a higher number of 
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upregulated genes than downregulated genes upon lamin B1 depletion. By 
analyzing the data of RNA-seq, we observed upregulation of RET proto-
oncogene and its co-receptor Gfra1, which are well known as positive 
regulators of cancer migration and metastasis (Mulligan, 2014). Moreover, we 
observed a high enrichment of lamin B1 at Ret promoter in MLE12 cells by ChIP 
analysis. Rationally this occupancy is profoundly disrupted by lamin B1 loss of 
function. In consistence with our own ChIP-seq data, we also found a 
localization of Ret gene in LADs by analyzing a published ChIP-seq data in 
human lung tissue (Shah et al., 2013), suggesting a direct role of lamin B1 in 
transcriptional repression of Ret gene. 
Besides, other migration related genes are also upregulated upon lamin B1 
depletion. For instance, in consistence with a published study showing an 
indispensable role of β3 integrin (Itgb3) in RET-induced cell invasion and 
migration (Cockburn et al., 2010), we also observed increased levels of Itgb3 
in lamin B1 knockdown cells in comparison with control cells. Other than Itgb3, 
in alignment with another study showing that ITGA9 was upregulated by 
chimeric oncogene RET/PTC1 in thyroid tumors (Degl'Innocenti et al., 2010), 
we also observed the upregulation of Itga9 upon lamin B1 depletion. The 
increased levels of critical factors required for RET-mediated migration and 
invasion upon lamin B1 loss, including Gfra1, Itgb3 and Itga9, suggest a 
mechanism by which lamin B1 reinforces RET function in cell migration and 
invasion. Indeed, we found that silencing of RET dramatically reduced the 
highly elevated migratory and metastatic ability of lamin B1-depleted cells by 
both in vitro and in vivo studies. Taken together, these data suggest that 
upregulation of RET plays a critical role in mediating migration and metastasis 
phenotype upon lamin B1 loss of function.  
Receptor tyrosine kinase RET is indispensable for a proper development of 
neural and genitourinary tissues (Mulligan, 2014). Deregulation of RET 
expression and activity, either by gain-of-function mutations or by altering 
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binding of ligands with RET co-receptors, is a critical contributor to several 
human cancers. Particularly in lung cancer, several studies show that gain-of-
function RET rearrangement KIF5B–RET, which induces constitutively active 
cytosolic chimeric proteins, leads to a subset of NSCLCs and plays an 
important role in driving lung cancer progression and malignancy (Dabir et al., 
2014; Ju et al., 2012; Kohno et al., 2012; Takeuchi et al., 2012). 
Moreover, we observed high incidence of SCLC in lamin B1 haploinsufficient 
mice. Importantly, in agreement with another study showing a high RET 
expression in SCLC tumor specimens (Dabir et al., 2014), we also observed 
that these SCLC tumors developed in lamin B1 haploinsufficient mice showed 
a high expression level of RET. Considering the neuroendocrine origin of SCLC 
(Sutherland et al., 2011), this finding also supports other studies showing that 
deregulation of RET signaling is mostly observed in neuroendocrine cancers 
(Mulligan, 2014). Besides, oncogenic RET mutations and copy number 
amplification were found in lung cancer specimens (Dabir et al., 2014; Kohno 
et al., 2012; Takeuchi et al., 2012; Yang and Horten, 2014). In line with this, we 
also observed high RET expression in different types of lung cancer specimens. 
Most importantly, RET expression in lung cancer patients is negatively 
correlated with lamin B1 level, supporting a link between gain of RET and loss 
of lamin B1 in human lung cancer patients. Other than RET, the 
activated/phosphorylated RET (phosphorylation of tyrosine 1062) is also highly 
expressed in the pulmonary tumors in Lmnb1+/- mice, suggesting that RET 
activation might also play a key role in lung cancer initiation, progression and 
metastasis upon lamin B1 loss of function. 
4.5 RET/p38 axis is responsible for lamin B1 depletion-
mediated cancer cell migration and metastasis 
As a receptor tyrosine kinase, activated/phosphorylated RET activates a variety 
of cell signaling pathways (Mulligan, 2014). In particular, phosphorylation of 
Discussion 
91 
 
tyrosine 1062 is crucial for activation of PI3K/AKT, p38 MAPK, JNK and ERK 
pathways. Activated p38 MAPK signaling pathway plays critical roles in 
mediating EMT and driving cancer cell migration and metastasis (Al-Mulla et al., 
2011; Bakin et al., 2002; Lin et al., 2016). In line with this, we found a high level 
of activated p38 along with the upregulation and activation of RET in lamin B1-
depleted lung epithelial cells as well as in lamin B1 haploinsufficient mice.  
Our study sheds a light on the molecular mechanism by which loss of lamin B1 
results in lung cancer migration and metastasis by upregulating RET and the 
subsequent metastatic events, including EMT and activation of p38 signaling 
pathway. We found that RET inhibitor vandetanib or p38 inhibitor SB202190 
efficiently reduced the migration mediated by lamin B1 depletion, suggesting a 
therapeutic potential of both vandetanib and SB202190 to clinically inhibit 
metastasis of cancer cells with decreased lamin B1 expression. Indeed, the 
application of vandetanib in patients with RET-rearranged metastatic non–
small-cell lung cancer is currently undergoing phase II clinical trials evaluation 
(ClinicalTrials.gov Identifier: NCT01823068) (Lee et al., 2017). Other than 
vandetanib, the benefit of other RET inhibitors (cabozantinib and lenvatinib), in 
terms of response and median progression free survival of NSCLC patients with 
activating RET rearrangements and mutations, has been demonstrated in 
several clinical trials (reviewed in Mendoza, 2018 (Mendoza, 2018)). Ongoing 
early phase clinical trials using the highly potent and selective RET kinase 
inhibitors, BLU-667 and LOXO-292, have generated great interest, given the 
high level of response and very mild toxicity profiles (Subbiah et al., 2018a; 
Subbiah et al., 2018b). 
4.6 Loss of lamin B1 leads to specific gene repositioning and 
chromatin decondensation  
Numerous studies have shown the link between gene repositioning and gene 
activity. In some cases gene repositioning leads to changes in gene activity, 
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however, in other cases it does not (reviewed in Shachar and Misteli, 2017 
(Shachar and Misteli, 2017)). We found that loss of lamin B1 led to RET 
repositioning from the nuclear lamina toward the center, concomitant with RET 
upregulation. Interestingly, knockdown of Ascl1 in lamin B1 depleted MLE12 
cells led to significantly downregulation of RET without affecting Ret gene 
positioning, suggesting that Ret gene repositioning is not sufficient to activate 
Ret gene expression. Furthermore, knockdown of EZH1 or EZH2 showed no 
effect on Ret gene repositioning, but elicited a significant increase in RET 
expression and migratory capacity of MLE12 cells, suggesting that not only lack 
of tethering to the nuclear periphery but also loss of EZH1/2 binding to 
chromatin is essential for Ret gene activation. 
Moreover, chromosome painting revealed that Chromosome 6, which harbors 
the highest percentage of upregulated genes, is decondensed and located 
more centrally in lamin B1-depleted cells. Taken together, these data suggest 
an important role of lamin B1 in chromatin positioning and compaction in lung 
epithelial cells.  
4.7 Lamin B1 depletion impedes the recruitment of EZH1/2, 
thus derepressing the transcription of Ret 
Nuclear lamins have been shown to repress gene expression via influencing 
chromatin structure and modification. In particular, lamins contribute to maintain 
the repressive heterochromatin makers in the target gene area, thus inhibiting 
the transcription of their target genes. Lamina-associated domains (LADs) 
tightly associate with heterochromatin and are enriched with histone 
modifications H3K9me2 and H3K9me3 which are the markers for 
heterochromatin (van Steensel and Belmont, 2017). In some cell types, 
facultative heterochromatin mark H3K27me3 is also enriched at LADs regions 
(van Steensel and Belmont, 2017). Consistently, in our study, we also observed 
a direct interaction between lamin B1 and H3K27me3. Importantly, we observed 
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a global decrease of H3K27me3 upon lamin B1 loss-of-function, suggesting a 
role of lamin B1 in modulating H3K27me3, thereby influencing the transcription 
of its target genes, such as RET. Decreased H3K27me3 might lead to increase 
in chromatin accessibility, transcription factor binding and RNA polymerase 
recruitment at lamin B1 associated genes, thus resulting in transcriptional 
activation. Consistent with this, in lamin B1-depleted cells we observed an 
increased enrichment of transcription factor Ascl1 at the Ret promoter. 
Importantly, Ascl1 has been shown to directly activate RET expression and play 
a critical role in lung cancer development (Augustyn et al., 2014; Borromeo et 
al., 2016).  
Furthermore, we found that lamin B1 depletion led to a decrease in the 
recruitment of EZH1/2 to chromatin and Ret promoter without affecting the 
protein level of EZH1/2. These data suggest that lamin B1 function as a scaffold 
to facilitate the proper landing of EZH1/2 to the chromatin and Ret promoter, 
which is indispensable for the role of EZH1/2 to catalyze H3K27me3. Indeed, 
we observed a direct lamin B1-EZH1/2 interaction in MLE12 cells. However, in 
the absence of lamin B1, EZH1/2 lost the ability to bind to chromatin due to the 
disruption of lamin B1- EZH1/2 interaction, thus failing to catalyze H3K27me3 
at the Ret promoter. In fact, it has already been shown that nuclear lamins act 
as a dynamic molecular scaffold for chromatin and chromatin 
interacting/modifying proteins, thus playing an important role in chromatin 
organization, DNA replication as well as transcription (Bridger et al., 2007; 
Dechat et al., 2008; Dorner et al., 2007).  
4.8 EZH1/2 mediate the function of lamin B1 in regulating cell 
migration 
Similar to lamin B1, the role of EZH1/2 and H3K27me3 in cancer initiation, 
progression and metastasis are also context and cancer type- specific. In 
particular, the role of EZH1/2 and H3K27me3 in lung cancer appears to be a 
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complex picture. On the one hand, several studies support an oncogenic role 
of EZH2 in NSCLC and define EZH2 as a prognostic marker and a therapeutic 
target, prospecting EZH2 inhibition as anti-cancer treatment(Fillmore et al., 
2015; Takawa et al., 2011). However, several other recent studies also showed 
a tumor-suppressive function of EZH1/2 in NSCLC (Li et al., 2014; Serresi et 
al., 2016). In alignment with these studies, our data show that inhibition of 
EZH1/2, either by inhibitor treatment or by shRNA-mediated depletion, 
dramatically increased the mRNA level of RET and induced migratory capacity 
of MLE12 cells, suggesting an anti-tumor role of EZH1 and EZH2 in lung. 
Importantly, the increased migratory ability of MLE12 cells upon EZH1/2 loss of 
function was significantly reduced by RET inhibitor treatment. It suggests that 
RET functions as a downstream target of EZH1 and EZH2. Moreover, several 
recent studies showed a promoting role of EZH1/2 and H3K27me3 inhibition in 
EMT (Cardenas et al., 2016; Li et al., 2015; Ramadoss et al., 2012), which 
supports our finding that EZH1/2 loss of function upon lamin B1 depletion 
facilitates lung cancer metastasis by upregulating RET and inducing EMT. Thus, 
our study, in alignment with other above-mentioned studies, suggests a better 
therapeutic strategy to lung cancer metastasis by targeting molecules 
downstream of the lamin B1-EZH1/2 axis.  
In addition, lamin A/C has been reported to sustain PRC2-mediated chromatin 
structure and loss of lamin A/C led to impaired PRC2 repressive function 
(Cesarini et al., 2015). Considering that A- and B-type lamins form separate but 
interacting structures, thus lamin B1 might lead to changes in lamin A/C function 
thereby indirectly influencing EZH1/2 function in a lamin A/C dependent manner. 
However, our data revealed that loss of lamin B1 did not affect the expression 
of lamin A/C. Importantly, in contrast to lamin B1 loss of function, silencing of 
lamin A did not have any effect on Ret gene positioning and expression or cell 
migration, suggesting a specific role of lamin B1 in gene regulation and EMT in 
mouse lung epithelial cells. 
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In addition, we observed a more profound upregulation of RET upon EZH1 
knockdown than EZH2 knockdown. Similarly, EZH1 depletion leads to a 
significantly higher increase in cell migratory ability than EZH2 depletion does. 
These data suggest a more prominent role of EZH1 than EZH2 in mediating the 
malignant phenotype of lung epithelial cells with reduced lamin B1 levels. In 
support of this finding, Kaplan-Meier survival curve showed that lung cancer 
patients expressing low levels of EZH1 had a significantly poorer prognosis 
than patients with higher EZH1 expression. Indeed, many studies have shown 
that EZH1 and EZH2 containing complexes have both common and distinct 
functions (Margueron et al., 2008; Shen et al., 2008). EZH1 maintains 
H3K27me3 in terminally differentiated cells, whereas EZH2 establishes and 
maintains H3K27me3 in proliferating cells (Margueron et al., 2008). In support 
of this, we observed a markedly higher enrichment of EZH1 in comparison with 
EZH2 at the Ret promoter. Furthermore, EZH1 and EZH2 also show different 
biochemical properties. EZH2 has higher catalytic activity towards H3K27me3 
than EZH1 and binds to chromatin through JARID2 (Son et al., 2013), whereas 
EZH1 binds to nucleosomes and induces chromatin compaction independently 
of PRC1 recruitment (Margueron et al., 2008), suggesting a role of EZH1 loss 
in chromatin decompaction upon lamin B1 loss. 
Taken together, our study demonstrates a novel role of loss of lamin B1 in 
promoting lung cancer development and metastasis by epigenetically 
upregulating proto-oncogene RET and RET-mediated epigenetically 
upregulation of EMT and activation of p38 signalling pathway. Therefore, 
targeting RET might be a novel therapeutic approach of a significant fraction of 
human lung cancers caused by perturbation of the lamin B1-EZH1/2. 
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5. Future perspective 
In the present study, we for the first time demonstrate a novel role of lamin B1 
loss of function in promoting lung cancer metastasis by upregulating RET/p38 
axis. Loss of lamin B1 upregulate genes which are mainly correlated with 
possitive regulation of cell migration and metastasis in mouse lung epithelial 
cells. Therefore we hypothesize that lamin B1, instead of randomly binding to 
the genome in lung epithelial cells, might specifically associates with genes with 
specific biologic functions. To corroborate this hypothesis, ChIP followed by 
sequencing analysis with a lamin B1 specific antibody will help to visualize the 
genomic binding profile of lamin B1 in lung epithelial cells as well as in lung 
cancer patients, thus uncovering the mechanism by which loss of lamin B1 
leads to upregulation of genes with certain biologic functions, for instance cell 
migration and metastasis.  
In addition to cancer cell migration and metastais, we also found a promoting 
role of lamin B1 loss of function in lung cancer initiation and malignancy. 
However, the molecular mechanism remains to be defined. Previous study in 
our group observed an increase in DNA damage and genomic instability as well 
as a disrupted DNA damage repair process upon lamin B1 depletion. Given the 
fact that oncogenic mutations, which mainly result from DNA damage and 
genomic instability, are major diver of tumorigenesis, therefore, discovering the 
oncogenic mutations occuring upon lamin B1 loss of function is critical to clarify 
the mechanism by which loss of lamin B1 triggers lung cancer initiation. In this 
case, performing whole exome sequencing (WES) or whole genome 
sequencing (WGS) on the pulmonary tumors of Lmnb1+/- mice would help to 
reveal the potential oncogenic mutations upon lamin B1 depletion and how 
similar they are to human lung cancer. In addition, by doing WES or WGS on 
the metastatic tumors in the kidneys and livers of Lmnb+/- mice would help to 
corroborate the origin of these tumors. Moreover, we observed chromosome 
decompaction upon lamin B1 loss in lung epithelial cells that could lead to 
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cancer-causing chromosome rearrangement. Multicolor-FISH technology 
based karyotyping will help to identify the potential carcinogenic chromosome 
rearrangement upon lamin B1 loss.  
In our study, most of the tumors in Lmnb1+/- mice showed strikingly similar 
characteristics to small cell lung cancer. Biallelic loss of Rb1 and Tp53 is 
observed in nearly 100% of human SCLC and has been identified as the 
predominant driver of SCLC. Thus, checking the status of Rb1 and Tp53 in the 
pulmonary tumors of Lmnb1+/- mice would help to identify whether Lmnb1 
haploinsufficiency leads to loss of Rb1 and Tp53, thereby triggering SCLC 
formation.  
Moreover, The Lmnb1+/- mice used in the present study carried Cre-mediated 
heterozygous germline deletion of Lmnb1 gene. Therefore, single Lmnb1 
functional allele was deleted throughout the entire mouse. To further specifically 
study lamin B1 function in lung cancer development and metastasis, lung-
specific knockout of Lmnb1 by intratracheal intubation with Adeno-Cre viruses 
in Lmnb1flox/flox mice will be helpful. 
An intriguing question that needs further investigation concerns the upstream 
mechanisms leading to lamin B1 downregulation in lung cancer patients, which 
may involve e.g. truncating or missense mutations, DNA deletions or epigenetic 
mechanisms such as promoter hypermethylation. For example, the CpG island 
promoter hypermethylation leads to lamin A/C silencing in lymphoma and 
neuroblastoma cells (Agrelo et al., 2005; Rauschert et al., 2017). Since LMNB1 
has a TATA-less CpG island-associated promoter, promoter hypermethylation 
might be also responsible for LMNB1 downregulation. Indeed, previous study 
in our group revealed that promoter of LMNB1 gene is hypermethylated in lung 
cancer specimens. It shows the reason how lamin B1 expression is significantly 
downregulated in lung cancer specimens in comparison to the normal lung 
tissue. However, the cause of the DNA hypermethylation at the promoter of 
LMNB1 gene remains to be defined. DNA affinity chromatography-pulldown of 
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LMNB1 promoter sequence followed by mass spectrometry analysis will help 
to identify the multiprotein complex and enzyme system which are responsible 
for the hypermethylation of LMNB1 promoter in lung cancer specimens. 
Moreover, our data demonstrate that lamin B1 acts as a scaffold to provide a 
platform for the interaction between EZH1/2, chromatin and Ret promoter. Loss 
of lamin B1 leads to global dissociation of EZH1/2 from chromatin as well as 
Ret promoter. However, how EZH1 and EZH2 are recruited to lamin B1, 
chromatin as well as Ret promoter still remains to be defined. Co-
immunoprecipitation of EZH1/2 followed by mass spectrometry or sequencing 
analysis might help to define novel subunits of the functional complex, such as 
functional proteins or non-coding RNAs, which could play a role as a navigator 
to guide EZH1/2 to chromatin and the Ret promoter.  
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6. Materials and Methods 
6.1 Materials 
6.1.1 Chemicals and compounds 
Substance   Supplier Reference 
number 
1-Phenyl-2-thiourea (PTU) Acros 207250250 
2-Log DNA ladder (0.1-10.0 kb) NEB #N3200L 
Acetic anhydride ((CH3CO)2O) Sigma-Aldrich A6404-
200ML 
Agarose, low melt Roth 6351.2 
Agarose NEEO Ultra Roth 2267,3 
Noble agar Sigma-Aldrich A5431 
Albumin fraction V (BSA) Roth 8076.2 
Ammonium persulfate (APS) ((NH4)2S2O8) Sigma-Aldrich A3678-25G 
Ampicillin sodium salt Sigma-Aldrich A99518-25G 
BM purple AP substrate, precipitating Roche 11 442 074 
001 
Bradford reagent, ready-to-use Fermentas R1271 
Chloroform (CHCl3) Roth Y015,1 
Chlorophenolred-ß-D-galactopyranoside 
(CPRG) 
Sigma-Aldrich 59767 
ddH2O     
DEAB (4-diethylaminobenzaldehyde) Sigma-Aldrich 31830 
Dimethyl sulfoxide (DMSO) ((CH3)2SO) Sigma-Aldrich D-8779 
dNTP (Nucleoside triphosphate) Set 1 Roth 178,1 
DTT (Dithiothreitol) (C4H10O2S2) Roth 6908.3 
Dry-milk, non fat milk BIO-RAD 170-6404 
EGTA (ethylene glycol tetraacetic acid) 
(C14H24N2O10)  
Roth 3054.2 
Ethanol denatured (CH3CH2OH) Roth K928,3 
Ethanol pro analysis (CH3CH2OH) Merck 1,00983,2511 
Ethidium bromide solution (C21H20BrN3) Sigma-Aldrich E1510-10ML 
Ethylenediaminetetraacetic acid (EDTA) 
(C10H16N2O8) 
Sigma-Aldrich E5134-250G 
FuGENE® HD Transfection Reagent Roche 4709705/100 
Formamide (CH3NO) Fluka 47670 
Gelatin from bovine skin, Type B Sigma-Aldrich G9391-100g 
Glutaraldehyde (CH2(CH2CHO)2) Sigma-Aldrich G5882-10ML 
Glycerol (C3H8O3) Roth 3783,1 
Glycine (NH2CH2COOH) Sigma-Aldrich 15527 
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Substance   Supplier Reference 
number 
Hexadimethrine bromide (polybrene) Sigma-Aldrich  #H9268 
Isopropanol (C3H8O) Roth 6752,4 
Kanamycinsulfate Roth T832,1 
LB-agar (Lennox) Roth X965,2 
LB-medium (Lennox) Roth X964,2 
Levamisole (C11H12N2S ) Fluka 31742 
Lithium chloride (LiCl) Roth 3739.1 
Maleic acid (C4H4O4) Roth K304.1 
Methanol (CH3OH) Roth 4627,5 
MG-132 Calbiochem 474790 
Magnesium chloride (MgCl2) Sigma-Aldrich M2393-500G 
Magnesium sulfate (MgSO4) Fischer 
Scientific 
M120,37 
Magnesium sulfate-heptahydrate 
(MgSO4·7H2O) 
Merck 1.05886.0500 
TEMED (Tetramethylethylenediamine) 
((CH3)2NCH2CH2N(CH3)2) 
Roth 2367,1 
Nonidet P-40 (NP-40) Fluka 74385 
Paraformaldehyde (PFA) (OH(CH2O)nH (n = 
8 - 100)) 
Sigma-Aldrich 15,812-7 
Phenol red (C19H14O5S) Sigma-Aldrich P0290 
Phosphatase inhibitor Cocktail set V Calbiochem 524632 
PIPES (Piperazine-N,N′-bis(2-
ethanesulfonic acid)) (C8H18N2O6S2) 
Sigma-Aldrich P1851 
PMSF (Phenylmethylsulfonyl fluoride) 
(C7H7FO2S) 
Serva 32395 
Poly(2-hydroxyethylmethacrylate) 
PoliHEMA 
Sigma-Aldrich P3932-10G 
Potassium chloride (KCl) Roth 6781.3 
Potassium hexacyanidoferrate (II) trihydrate Sigma-Aldrich P9387 
Potassium hexacyanoferrate (III) Sigma-Aldrich P8131-100G 
Prestained protein molecular weight marker Fermentas #SM0441 
Protease inhibitor cocktail set I  Calbiochem 535142 
Puromycin Sigma-Aldrich  #P8833 
Rotiphorese® Gel 30 (37.5:1) Roth 3029.1 
Salmon sperm DNA Upstate 16-157 
Sodium dodecyl sulfate (SDS) 
(NaC12H25SO4) 
Sigma-Aldrich L4390-100G 
Sodium phosphate monobasic monohydrate 
(NaH2PO4 · H2O) 
Sigma-Aldrich 53522-1KG 
Sodium phosphate dibasic dodecahydrate Sigma-Aldrich 04273 
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Substance   Supplier Reference 
number 
(Na2HPO4 · 12H2O) 
TRIzol® reagent Invitrogen 15596026 
Triethanolamine (C6H15NO3) Sigma-Aldrich T1377-
500ML 
Tricaine methane sulphonate (Tricaine) 
(C10H15NO5S) 
Pharmaq MS222-
100G-V1 
TRIS (tris(hydroxymethyl)aminomethane) 
((HOCH2)3CNH2) 
Roth 4855.2 
Sodium citrate dihydrate Sigma-Aldrich W302600 
Triton X-100 ((C14H22O(C2H4O)n)) Sigma-Aldrich X100-500ML 
Tween 20 EP, NF Sigma-Aldrich T2700-
500ML 
Yeast tRNA Roche 10 109 517 
001 
X-gal Roth 2315.2 
β-mercaptoethanol (C2H6SO) Sigma-Aldrich 60-24-2  
Xylene Roth CN80.2 
Vandetanib Selleckchem S1046 
SB202190 Adipogen AG-CR1-
0028 
UNC1999 Sigma-Aldrich 1431612-23-
5 
CellTiter 96® AQueous One Solution Cell 
Proliferation Assay (MTS) 
Promega G3580 
6.1.2 Kits 
Kit Supplier 
2x SYBRGreen Applied Biosystems 
Duolink® In Situ Orange Starter Kit Goat/Rabbit Sigma-Aldrich 
VECTASTAIN Universal Quick HRP Kit Vector Laboratories 
DAB Peroxidase (HRP) Substrate Kit Vector Laboratories 
RNeasy Microarray kit Qiagen 
MinElute PCR Purification Kit Qiagen 
GenEluteTM gel extraction kit Sigma-Aldrich 
GenEluteTM HP plasmid midiprep kit Sigma-Aldrich 
GenEluteTM HP plasmid miniprep kit Sigma-Aldrich 
GenEluteTM PCR clean-up kit Sigma-Aldrich 
High-Capacity cDNA Reverse Transcription Kit Applied Biosystems 
PowerUp™ SYBR™ Green Master Mix Applied Biosystems 
RedTaq® ReadyMix TM PCR Reaction Mix Sigma-Aldrich 
Thermo Scientific™ Pierce™ BCA™ Protein Assay Thermo Fisher 
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Kit Supplier 
Scientific 
Subcellular Protein Fractionation Kit for Cultured 
Cells 
Thermo Fisher 
Scientific 
Nick Translation Kit Roche 
6.1.3 Solutions, reagents and media 
Name Composition or supplier 
10% Ammonium persulfate 0.44M Ammonium 
persulfate (H8N2O8S2) 
2x SDS PAGE sample buffer 150mM TRIS pH=6.8 
(added in solution) 
1.2% (v/v) SDS 
30% (v/v) glycerol 
6.7% (v/v) β-
mercaptoethanol 
1.8mg bromophenol blue 
10x PBS 1.37M NaCl 
27mM KCl 
0.1M Na2HPO4 · 12H2O 
17.6mM KH2PO4 
(pH titrated to 7.4) 
PBST 0.05% (v/v) Tween 20  
in 1xPBS 
Blotting buffer 20% (v/v) methanol 
192mM glycine 
25mM TRIS 
Buffer A (cytosolic/nuclear fractioning) 10mM HEPES pH=7.9 
(added in solution) 
10mM KCl 
1.5mM MgCl2 
Buffer B (cytosolic/nuclear fractioning) 0.45M NaCl 
12.5% (w/v) glycerol 
15mM HEPES pH=7.9 
(added in solution) 
5mM KCl 
1.5mM MgCl2 
0.1mM EDTA 
10x agarose gel sample buffer 250mg/100ml (w/v) 
bromophenol blue 
250mg/100ml (w/v) xylene 
cyanol 
50mM TRIS pH=7.6 (added 
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Name Composition or supplier 
in solution) 
60% (v/v) glycerol 
10x SDS PAGE running buffer 35mM SDS 
250mM TRIS 
0.86M glycin 
2x RNA-loading dye 100µl Formamide 
40µl Formaldehyde 
20µl 10xTBE 
2µl Ethidium bromide 
10x TBE 0.89M TRIS 
0.89M H3BO3 
20mM Na2EDTA pH=8.0 
Co-IP buffer 50mM TRIS-HCl pH=7.5  
15mM EGTA 
100mM NaCl 
0.1% (v/v) Triton X-100 
Stripping solution 1 200mM glycine 
500mM NaCl 
(pH titrated to 2.8) 
Stripping solution 2 200mM glycine 
500mM NaCl 
(pH titrated to 2.2) 
Stripping solution 3 200mM TRIS-HCl 
(pH titrated to 7.4) 
Washing buffer 0.1% (v/v) Tween 20 
in PBS 
L1 lysis buffer (ChIP) 50 mM Tris pH=8  
2mM EDTA pH=8  
0.1% (v/v) NP40 
10% (v/v) glycerol 
L2 nuclear resuspension buffer (ChIP) 50mM Tris pH=8 
5mM EDTA pH=8  
1% (w/v) SDS 
DB-dilution buffer (ChIP) 200mM NaCl 
50mM Tris pH=8  
5mM EDTA, 50mM 
0.5% NP40 
NaCl-washing buffer (ChIP) 500mM NaCl 
20mM Tris pH= 
2mM EDTA 
NP40 (v/v) 1% 
0.1% (w/v) SDS 
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Name Composition or supplier 
LiCl-washing buffer (ChIP) 500mM LiCl 
20mM Tris pH=8  
2mM EDTA 
1% (v/v) NP40 
0.1% (w/v) SDS 
EB-extraction buffer (ChIP) 10mM Tris pH=8  
1mM EDTA 
2% (w/v) SDS 
TE-buffer 10mM Tris pH=8  
1mM EDTA 
Tail Lysis Buffer 100 mM Tris pH=8.5 
5mM EDTA 
0.2% SDS 
200 mM NaCl 
100 µg/ml Proteinase K 
Cytoskeletal (CSK) buffer 10 mM PIPES, pH 6.8 
100 mM NaCl 
300 mM sucrose 
1 mM EGTA 
1 mM MgCl2 
DMEM 4.5g GlutMax GIBCO 
DMEM 4.5g without  GlutMax GIBCO 
RPMI 1640  GIBCO 
DMEM/F12 (1:1) GIBCO 
Fetal bovine serum GIBCO 
100x Pen/Strep GIBCO 
100x Pyruvate GIBCO 
100x Non-essential amino acids (NEAA) GIBCO 
100x L-glutamine GIBCO 
β-mercaptoethanol Sigma-Aldrich 
Matrigel® Growth Factor Reduced (GFR) 
Basement Membrane Matrix 
Corning (354230) 
Hematoxylin Solution Sigma-Aldrich (GHS116) 
Eosin Y solution Sigma-Aldrich (HT110216) 
Crystal violet solution Sigma-Aldrich (HT901) 
Fisher Chemical™ Permount™ Mounting 
Medium 
Fisher Scientific 
ProLong ™ Gold Antifade Mountant Thermo Fisher Scientific 
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6.1.4 Antibodies 
Name Company Cat. No. 
Lamin B1 Sigma-Aldrich HPA050524 
Lamin A/C Santa Cruz sc-6215 
Pan-Cytokeratin Dako Z0622 
CD45 Abcam ab10558 
CGRP Sigma-Aldrich c8198 
Synaptophysin Invitrogen PA5-27286 
Ki67 Abcam ab15580 
PCNA Santa Cruz sc-56 
E-cadherin Abcam ab11512 
Fibronectin Abcam ab2413 
N-cadherin Sigma-Aldrich c3865 
Vimentin CST 5741 
α-tubulin Sigma-Aldrich T5168   
RET Abcam ab134100 
RET Santa Cruz sc-167 
p-p38 (Thr180/Tyr182) CST 4511 
p38 CST 9212 
p-JNK (Thr183/Tyr185) CST 9255 
p-ERK1/2 Santa Cruz sc-7383 
p-RET (Tyr 1062) Santa Cruz sc-20252-R 
EZH1 Abcam ab13665 
EZH2 Abcam ab3748 
H3K27me3 Millipore 07-449 
H3K9me2 Abcam ab1220 
H3K9me3 Abcam ab8898 
Histone H3 Abcam ab1791 
Ascl1 BD Pharmingen 556604 
Pol II Abcam ab817 
Anti-Digoxigenin Fab fragments  Sigma-Aldrich 11207750910 
 
6.1.5 Primers 
 
Primer Sequence (5’-3’) 
Lmnb1 forward M. musculus 
Lmnb1 reverse M. musculus 
AGATCAGGGACCAGATGCAG 
GAAGGGCTTGGAGAGAGCTT 
Lmnb1 forward H. sapiens GACCAGCTGCTCCTCAACTATG 
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Primer Sequence (5’-3’) 
Lmnb1 reverse H. sapiens ATTCTCGAAGCTTGATCTGGGC 
Lmna forward M. musculus GGAAGTCGATGAAGAGGGAAAG 
Lmna reverse M. musculus TTTAGGGTGAACTTCGGTGG 
Tuba1a forward M. musculus 
Tuba1a reverse M. musculus 
CCGCGAAGCAGCAACCAT  
CCAGGTCTACGAACACTGCC  
Tuba1a forward H. sapiens GAAGCAGCAACCATGCGTGA 
Tuba1a reverse H. sapiens TCTCCTCCCCCAATGGTCTT 
RET forward M. musculus 
RET reverse M. musculus 
ACACGGCTGCATGAGAATGA 
GGAAACCACCATTGCGGATG   
RET forward H. sapiens GAAGGCGACGTCCGGTG 
RET reverse H. sapiens TAGAGGCCCAATGCCACTTT 
Gfra1 forward M. musculus 
Gfra1 reverse M. musculus 
TTTCCAGCAAGTGGAACACA   
GCGGTTGCAGACTTCATTGG   
Ascl1 forward M. musculus CCCTCTTAGCCCAGAGGAAC 
Ascl1 reverse M. musculus TGCCATCCTGCTTCCAAAGTC 
EZH1 forward M. musculus TCCATGAGGAAAATGGATATAGCA 
EZH1 reverse M. musculus TCCCATATTTGCCTGGAGCC 
EZH2 forward M. musculus ACTGCTTCCTACATCCCTTCC  
EZH2 reverse M. musculus ACGCTCAGCAGTAAGAGCAG 
Ret promoter forward M. musculus GAAAGAGGGACAGAGAGCCT 
Ret promoter reverse M. musculus GACAACGGTAGCAGGTCTCT 
RET promoter forward H. sapiens TAGCCGCAGTCCCTCCAG 
RET promoter reverse H. sapiens CCCACGGCAAACAGAAAGG 
Gfra1 promoter forward M. musculus GACCCGCTTTTAGGGGTTCA 
Gfra1 promoter reverse M. musculus CTTCAGCACTCTGGGCTCTC 
GFRA1 promoter forward H. sapiens TGCGGTAATCTTCGAGAGCT 
GFRA1 promoter reverse H. sapiens GAACAGGAGCAGGCCGAG 
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6.1.6 Cell lines and plasmids 
MLE12, LLC1, BEAS-2B (B2B), NCI-H69 (H69) and HEK293T cells were 
purchased from ATCC (CRL-2110, CRL-1642, CRL-9609, HTB-119, CRL-3216). 
Control shRNA and shRNA against mouse Lmnb1 (SHCLNG-NM_010721), 
human Lmnb1 (SHCLND-NM_005573), mouse Lmna (SHCLNG-
NM_001002011.2), mouse RET (SHCLNG-NM_009050), mouse Ascl1 
(SHCLNG-NM_008553.4), EZH1 (SHCLND-NM_007970) and EZH2 
(SHCLND-NM_007971) were obtained from MISSION™ shRNA Library, 
Sigma-Aldrich.  
6.1.7 Mouse lines 
The Lmnb1 tm1a (EUCOMM)Wtsi mouse line was obtained from Genome 
Research Limited (Sanger, UK). C57BL/6J werer obtained from Charles River 
Laboratory. 
6.2 Methods 
6.2.1 Cell culture and generating stable cell lines 
MLE12 cells were cultured in DMEM/F12 medium supplemented with 10% fetal 
bovine serum (FCS) and penicillin/streptomycin/glutamine (PSG). HEK293T 
and LLC1 cells were cultured in DMEM supplemented with 10% FCS and PSG. 
B2B and H69 cells were cultured in RPMI1640 supplemented with 10% FCS 
and PSG. 
For the generation of stable cell lines, 0.5×106 HEK293T cells were plated on a 
6-well plate and transfected with 2 µg of plasmids containing shRNA or control 
and RET overexpressing constructs, along with packaging plasmids and 
envelop plasmid, using FuGENE (Roche) transfection reagent. Media 
containing lentivirus was harvested 48 hrs after transfection, followed by 
centrifugation at 4,200 rpm for 20 min to pellet any packaging cells that were 
collected during harvesting. Viral supernatant together with polybrene (working 
concentration.: 8µg/ml) was added into the cells to be transduced. After 24 hrs, 
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viral medium was removed and complete culturing medium was added into the 
cells. After 24 hrs, transfected cells were selected with 10 µg/ml puromycin for 
2 passages and selected cells were maintained with 2 µg/ml puromycin as 
stable cell lines. All cell lines used in the present study were free from 
mycoplasma contamination. 
6.2.2 Immunohistochemistry and immunofluorescence staining 
6.2.2.1 Immunohistochemical staining on paraffin sections 
For immunohistochemical (IHC) staining on paraffin sections, slides were 
heated at 55 °C for 10 min and submerged into xylene (Sigma-Aldrich), followed 
by serial deparaffinization and rehydration steps (3 times xylene, 3 times 100% 
ethanol, 90% ethanol, 75% ethanol, 50% ethanol, distilled water, each 5 min). 
Antigen retrieval was done by microwave boiling in 10 mM citrate buffer for 10 
min. The subsequent steps were done with the VECTASTAIN Universal Quick 
HRP Kit (PK-7800, Vector Laboratories) following the manufacturer’s 
instructions. In detail, after antigen retrieval, slides were blocked with blocking 
serum for 1 hour, followed by incubation in primary antibody diluted in blocking 
serum at 4°C overnight. On the next day, slides were washed for 5 min with 
PBS. Slides were incubated with biotinylated panspecific universal secondary 
antibody for 10 minutes, followed by washing for 5 minutes with PBS. Next 
slides were incubated with streptavidin/peroxidase complex reagent for 5 
minutes, followed by washing for 5 minutes with PBS. Staining was then 
developed with DAB Peroxidase (HRP) Substrate Kit (SK-4100, Vector 
Laboratories) and counterstained with hematoxylin solution for 30 seconds. 
Slides were then quickly dehydrated by incubation in a series of ethanol 
solutions with increasing concentrations (50%, 75%, 90%, 3×100%) for 5 min 
each. Next slides were washed in 2 changes of xylene for 5 minutes each and 
then mount with xylene based mounting medium. 
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6.2.2.2 Immunofluorescence staining on paraffin sections 
For immunofluorescence staining on paraffin sections, slides were 
deparaffinized, rehydrated and followed by antigen retrieval in the same way as 
described for IHC staining on paraffin sections. Slides were then blocked with 
10% FCS with 0.5% Triton X-100 (Sigma-Aldrich) in PBS for 1 hr and incubated 
with primary antibodies in blocking buffer at 4°C overnight. On the next day, 
slides were washed and secondary antibodies were added for 2 hr. Slides were 
then washed with PBS and mounted with anti-fade mounting medium. 
6.2.2.3 Immunofluorescence staining on cultured cells 
For immunofluorescence staining of cultured cells, cells were counted and 
seeded on coverslips in 24-well plates. Next, cells were washed with PBS and 
fixed with 3.7% formaldehyde for 10 min, followed by the same blocking and 
staining procedures as described for IF on paraffin sections. All of the 
fluorescence images were acquired using LSM 700 laser scanning microscope 
(Carl Zeiss Micro Imaging) with a 25× or 40× or 63× objective and analyzed 
with ImageJ (National Institutes of Health) or Zeiss ZEN Microscope Software 
(Carl Zeiss Micro Imaging). 
6.2.2.4 Immunohistochemical staining on tissue microarray 
For tissue microarray immunostaining and analysis, the tissue microarray slides 
were purchased from US Biomax Inc (LC2085c). The steps of deparaffinization, 
antigen retrieval, blocking and staining procedures were the same as described 
for IHC staining on paraffin sections. For lamin B1 and lamin A/C staining, only 
the nuclear staining signal of cancer cells excluding non-malignant stromal cells 
and immune cell was quantified. The quantification of the signal was performed 
by measurement of signal intensity and percentage of stained cells. The 
intensity of the staining signal was semiquantitatively graded on a scale from 0 
to 3 (lowest to highest). H-score of the staining was calculated by multiplying 
the staining intensity by the percentage of stained cells. The staining score 
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ranges from 0 to 300. 
6.2.2.5 Antibodies used for IHC and IF 
Name Company Cat. No. Dilution 
Lamin B1 Santa Cruz sc-6216 1:100 
Lamin B1 Sigma-Aldrich HPA050524 1:100 
Lamin A/C Santa Cruz sc-6215 1:100 
Pan-Cytokeratin Dako Z0622 1:300 
CD45 Abcam ab10558 1:200 
CGRP Sigma-Aldrich c8198 1:100 
Synaptophysin Invitrogen PA5-27286 1:100 
Ki67 Abcam ab15580 1:200 
PCNA Santa Cruz sc-56 1:100 
E-cadherin Abcam ab11512 1:150 
Fibronectin Abcam ab2413 1:100 
N-cadherin Sigma-Aldrich c3865 1:100 
Vimentin CST 5741 1:100 
RET Santa Cruz sc-167 1:50 
p-p38 (Thr180/Tyr182) CST 4511 1:100 
p-RET (Tyr 1062) Santa Cruz sc-20252-R 1:50 
EZH1 Abcam ab13665 1:100 
EZH2 Abcam ab3748 1:100 
 
6.2.3 Histology 
Lungs were perfused with PBS, dissected and fixed with 3.7% 
paraformaldehyde at room temperature for one day, followed by 3 washes with 
PBS. Tissues were dehydrated by incubation in a series of ethanol solutions 
with increasing concentrations. Ethanol was replaced by xylene and paraffin 
followed by embedding in paraffin. For hematoxylin and eosin (H&E) staining, 
slides were deparaffinized and rehydrated as described for IHC staining on 
paraffin sections. Slides were then stained with hematoxylin solution for 10 min, 
followed by washing in running tap water for 5 min. Slides were then stained 
with eosin solution for 5 min, followed by quick dehydration through incubation 
in a series of ethanol solutions with increasing concentrations. Slides were 
wash in 2 changes of xylene for 5 minutes each and then mount with xylene 
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based mounting medium. Images were captured by NanoZoomer 2.0-HT whole 
slide imager (Hamamatsu) or Axio Scan.Z1 (ZEISS) and analyzed by 
NDP.view2 Viewing software (Hamamatsu) or ZEN 2.3 SP1 (ZEISS), 
respectively. Representative images of histological analysis of mice with the 
same genotype are presented. 
6.2.4 Animal experiments 
All animal experiments were done in accordance to the institutional guidelines 
and are covered in an approved animal experimental protocol by the Committee 
for Animal Rights Protection of the State of Hessen (Regierungspraesidium 
Darmstadt, Germany, Experimental protocol Az.: V54 – 19 c 20/15 – B2/363 
and V54-19c20/15-B2/1113). 
The Lmnb1tm1a (EUCOMM)Wtsi mouse line was obtained from Genome 
Research Limited (Sanger, UK). Lmnb1tm1a were backcrossed to C57BL/6 for 
six generations before the use in these studies. 
Female C57/BL6 and BALB/c nu/nu mice were purchased from Charles Rivers, 
Sulzfeld, Germany and kept under pathogen-free conditions. 
For induction of experimental metastasis, 1×106 wild-type, control or lamin B1, 
RET and lamin B1/RET shRNA-expressing LLC1 cells were injected 
intravenously into 7-8 weeks old C57BL/6 mice, respectively. After 20 days 
(LLC1 cells) or 24 days (MLE12 cells), the mice were sacrificed and imaged, 
the lungs were isolated, imaged, fixed with 3.7% PFA and embedded into 
paraffin. 5 µm thick paraffin sections were stained with hematoxylin and eosin.  
For subcutaneous transplantation, 1×106 control or lamin B1, RET and lamin 
B1/RET shRNA-expressing LLC1 cells were injected into the flanks of C57BL/6 
mice (Charles River). After 20 days the mice were sacrificed, imaged and the 
subcutaneous tumors and lungs were isolated, imaged, fixed with 3.7% PFA 
and embedded into paraffin. 5 µm thick paraffin sections were used hematoxylin 
and eosin staining or IHC staining. 
Metastatic area was defined as the percentage of lung area occupied by 
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metastatic tumor, measured by ImageJ. Tumor volumes and number of tumor 
nodules in the lung were quantitated from H&E stained lung sections using 
ImageJ. 
6.2.5 Boyden chamber migration and invasion assay 
6.2.5.1 Transwell migration assay 
Falcon Cell Culture Inserts for 24 Well Plate with 8.0um Pore Transparent PET 
Membrane (Corning, Cat. No. 353097) were placed on 24-well plates 
containing 10% FCS medium. 1×105 MLE12 cells or 5 ×104 LLC1 cells or 1.2 
×105 B2B cells or 2 ×105 H69 cells were seeded on top of the insert in a 0 % 
FCS medium. 5 hrs later (for H69 cells, 24hrs later), the insert membranes were 
fixed with 3.7% formaldehyde for 10 min and washed 3 times with PBS. The 
upper surface of the membranes was cleaned by wiping with a piece of wet 
paper. Membranes were then stained with crystal violet for 10 minutes. Images 
of randomly selected areas were acquired with a 20x objective and the number 
of cells that had migrated to the lower surface of the membrane was quantified 
using ImageJ (http://imagej.nih.gov/ij/).  
6.2.5.2 Matrigel invasion assay 
The in vitro Matrigel invasion assay was essentially similar to the cell migration 
assay described above, except that the membrane filter was precoated with 50 
µl diluted Matrigel (diluted with serum free culture medium, final working 
concentration 1 mg/ml) for 2 hrs before seeding the cells. 24 hrs later, the insert 
membranes were fixed.  
6.2.6 Cell proliferation and soft agar colony formation assay  
Cell proliferation was measured using CellTiter 96 AQueous One Solution Cell 
Proliferation Assay (MTS) according to the manufacturer’s instructions. In detail, 
1000 cells were seeded into each well of a 96-well plate, and the cells were 
incubated for the 1, 2, 3, 4 and 5 days respectively. After incubation, CellTiter 
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96® AQueous One Solution Reagent were directly added to the culture wells 
followed by incubation for 1 hour. Absorbance, which is proportional to the 
number of living cells in culture was then measured at 490 nm with a 96-well 
plate reader. For soft agar colony formation assay, control and Lmnb1 KD 
MLE12 cells were suspended in complete DMEM/F12 medium containing 0.3% 
low melting agarose, and plated onto solidified 0.6% agarose in complete 
DMEM/F12 medium in 12-well culture plates at a density of 5 000 cells per well. 
After 14 days the colonies were stained with 0.005% Crystal Violet. 
6.2.7 RNA Isolation, RT-PCR and Real-Time PCR  
For real-time PCR analysis, RNA was isolated using the TRIzol RNA Isolation 
Reagent (Invitrogen). cDNA was synthesized with the High Capacity cDNA 
Reverse Transcription Kit (Applied Biosystems) according to the manual. Real-
time PCR was performed using the SYBR GREEN PCR master mix (Applied 
Biosystems). Cycle numbers were normalized to these of α-Tubulin (Tuba1a). 
Primer details are given in Chapter Primers. 
For RNA-Seq, the RNA was isolated using RNeasy Microarray kit (Qiagen 
#73304). 
6.2.8 RNA-Seq data analysis 
Raw RNA-seq reads were trimmed with reaper 
(http://www.ebi.ac.uk/~stijn/reaper/reaper.html) using the following parameters 
-geom no-bc -3pa -clean-length 20 -qqq-check 53/10 -trim-length 150 –nozip. 
Trimmed reads were mapped to the reference genome mm10 (UCSC assembly) 
using the default settings of STAR software (Dobin et al., 2013) (--
outFilterMismatchNoverLmax 0.1 --chimSegmentMin 18 --chimScoreMin 12). 
Differential expression (Log2FC≥1, FDR<0.05, BaseMean >=2 for upregulated 
genes, Log2FC≤-1, FDR<0.05, BaseMean >=2 for downreagulated genes) was 
quantified and normalized by the use of DESEq2. Gene ontology analysis was 
performed using DAVID Bioinformatics Resources 6.8, adjusted p-value (FDR) 
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for the GO terms was calculated in R using the Benjamini-Hochberg method 
(Benjamini and Hochberg, 1995). The percentage of up-regulated genes per 
chromosome was calculated by dividing the number of genes upregulated upon 
Lmnb1 KD in MLE12 cells at specific chromosome to the total number of 
upregulated genes. To determine the number of genes per chromosome a 
custom script in bash was developed. Briefly, the coordinate of mm10 
transcripts of Refseq database were obtained by using (analyzeRepeats.pl rna 
mm10 -strand both -count genes) and annotated by annotatePeaks.pl (default 
settings). Single genes per chomosomes were substracted with the help of a R 
script (mat_u <- mat[!duplicated(mat$gene_name),] followed by mat_u <- 
subset(mat_u, chr==n; where n is each chromosome)).  
6.2.9 Immunoprecipitation and immunoblotting 
6.2.9.1 Samples preparation 
For isolating nuclear extract, cells were lysed with buffer A (10 mM HEPES pH 
7.9, 1.5 mM MgCl2, 10 mM KCl, protease inhibitors SET-I (Sigma-Aldrich)) on 
ice for 10 min. 10% NP40 was added into the lysates (volume ratio is 1:16) and 
vortexed for 10 sec. Lysates were centrifuged at 12,000g for 30 sec at 4 °C. 
The supernatant (cytoplasmic extract) were removed and the pellets was 
resuspended with cold buffer B (15 mM HEPES pH 7.9, 12.5% glycerol, 1.5 mM 
MgCl2, 5 mM KCl, 0.1 mM EDTA, 0.45 M NaCl, protease inhibitors SET-I 
(Sigma-Aldrich) ) and incubated for 15 min at 4 °C. Lysates were centrifuged at 
12,000g for 5 min at 4 °C. The supernatant is nuclear extract. 
The chromatin bound fraction was isolated using Subcellular Protein 
Fractionation Kit for Cultured Cells (ThermoFisher Scientific) according to the 
manual. In detail, 2 × 106 cells were harvested into a 1.5 mL microcentrifuge 
tube and pellet by centrifugation at 500 × g for 5 minutes. Supernatant was then 
removed. Ice-cold Cytoplasmic Extraction Buffer (CEB) containing protease 
inhibitors was then added to the cell pellet followed by incubation at 4°C for 10 
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minutes by gentle mixing. Lysate was then centrifuged at 500 × g for 5 minutes. 
Supernatant (cytoplasmic extract) was removed and pellet was resuspended 
with ice-cold Membrane Extraction Buffer (MEB) containing protease inhibitors. 
After vortexing for 5 seconds on the highest setting, the lysate was incubated 
at 4°C for 10 minutes by gentle mixing. After centrifugation at 3000 × g for 5 
minutes, supernatant (membrane extract) was removed and pellet was 
resuspended with ice-cold Nuclear Extraction Buffer (NEB) containing protease 
inhibitors, followed by vortexing on the highest setting for 15 seconds and 
incubation at 4°C for 30 minutes by gentle mixing. After centrifugation at 5000 
× g for 5 minutes, supernatant (soluble nuclear extract) fraction was removed 
and pellet was resuspended with chromatin-bound extraction buffer (NEB 
containing protease inhibitors, CaCl2 and Micrococcal Nuclease), followed by 
Vortexing on the highest setting for 15 seconds and incubation at room 
temperature for 15 minutes. After incubation, lysate was vortexed on the highest 
setting for 15 seconds and centrifuged at 16,000 × g for 5 minutes. The 
supernatant is chromatin bound fraction. 
Total cell lysate was obtained by lysing the cells in co-IP buffer (50 mM Tris 
pH7.5, 100 mM NaCl, 15 mM EGTA, 0.1% Triton-X100, protease inhibitors 
SET-I (Sigma-Aldrich)), followed by sonication (Bandelin Sonopuls) for 10 sec. 
Lysates were then centrifuged at 12,000g for 10 min at 4 °C. The supernatant 
is total protein extract. 
6.2.9.2 Immunoprecipitation 
For Immunoprecipitation (co-IP), total cell lysates were obtained as described 
in chapter 6.2.9.1. For each co-IP experiment, 1mg total cell lysate was diluted 
with co-IP buffer (50 mM Tris pH7.5, 100 mM NaCl, 15 mM EGTA, 0.1% Triton-
X100, protease inhibitors SET-I (Sigma-Aldrich)) to 1ml. The diluted lysates 
were then incubated with 2µg indicated antibodies overnight at 4 °C followed 
by 3 hrs incubation with Protein-A/G-Sepharose beads (GE Healthcare). 
Immunoprecipitates were washed five times in 1ml co-IP buffer, dissolved in 
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30µl 2x SDS-PAGE sample buffer, and subjected to standard western blot 
analysis.  
6.2.9.3 Western blot 
Cell lysates were mixed with 5x SDS-PAGE loading buffer (250 mM Tris·HCl, 
pH 6.8, 10% SDS, 30% (v/v) Glycerol, 10 mM DTT, 0.05% (w/v) Bromophenol 
Blue) at the ratio 4:1 before boiling at 95°C for 10 min. Then the samples were 
loaded for electrophoresis. After electrophoresis, the gel was transferred 
carefully to a nitrocellulose membrane using a wet-transfer system at 90V for 1 
hour. After transfer, nitrocellulose membranes were stained with Ponceau G 
solution to validate transfer quality and loading equality. Then, the nitrocellulose 
membranes were briefly washed with PBS containing 0.5% Tween-20 before 
being blocked with PBS containing 5% non-fat dried milk and 0.5% Tween-20. 
The membranes were incubated with primary antibodies with appropriate 
dilutions overnight at 4 °C. After overnight incubation, the membranes were 
washed for 3 times for 10 minutes with PBST and incubated with HRP-
conjugated secondary antibodies for 1 hour at room temperature. After 3 times 
washes with PBST for 10min each, antigen-antibody complexes were detected 
and imaged using the ECL detection kit and digital western blot detection 
system. 
6.2.9.4 Antibodies used for western blot 
Name Company Cat. No. Dilution 
Lamin B1 Santa Cruz sc-6216 1:1000 
Lamin A/C Santa Cruz sc-6215 1:1000 
E-cadherin Abcam ab11512 1:2000 
Fibronectin Abcam ab2413 1:1000 
N-cadherin Sigma-Aldrich c3865 1:500 
α-tubulin Sigma-Aldrich T5168   1:8000 
RET Abcam ab134100 1:2000 
p-p38 (Thr180/Tyr182) CST 4511 1:1000 
p38 CST 9212 1:1000 
p-JNK (Thr183/Tyr185) CST 9255 1:2000 
p-ERK1/2 Santa Cruz sc-7383 1:1000 
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Name Company Cat. No. Dilution 
p-RET (Tyr 1062) Santa Cruz sc-20252-R 1:1000 
EZH1 Abcam ab13665 1:500 
EZH2 Abcam ab3748 1:1000 
H3K27me3 Millipore 07-449 1:2000 
Histone H3 Abcam ab1791 1:8000 
 
6.2.10 DNA Fluorescence In Situ Hybridization (FISH) 
DNA FISH probes were labeled with digoxigenin by Nick Translation kit (Roche) 
according to manufacturer’s protocol using BAC DNA clones: RET (RP23-
98B12, ThermoFisher) and Gfra1 (RP23-180P13, ThermoFisher). Whole 
chromosome painting probes for mouse chromosome 6 and 10 were purchased 
from MetaSystems Probes. For DNA FISH, cells were grown on coverslips, 
fixed with 4% formaldehyde for 10min, permeabilized with 0.5% Triton X-100 
for 10min. Cells were incubated with 20% glycerol/ PBS for 60min and then 
0.1N HCl for 20min. Cells were equilibrated in 2×SSC (1×SSC: 0.15M NaCl and 
0.015M sodium citrate, pH 7.0) for 5min and then in 50% formamide/2×SSC for 
30min. Next, labeled DNA probes were added to the cells, followed by co-
denaturation of cells and probes on a hot plate at 75 °C for 3 min and then 
incubation at 37°C for 24 hrs for the hybridization. Probes were detected by 10 
μg/ml anti-digoxigenin-rhodamine, Fab fragments (Roche) and cells were 
counterstained with DAPI. Images were captured with laser scanning 
microscopy LSM 700 (Carl Zeiss Micro Imaging) with 63× objective and 
analyzed with ImageJ (National Institutes of Health) or Zeiss ZEN Microscope 
Software (Carl Zeiss Micro Imaging). 
6.2.11 Proximity ligation assay (PLA) 
PLA was performed using Duolink® In Situ Orange Starter Kit Goat/Rabbit (Cat. 
No.: DUO92106, Sigma-Aldrich) following the manufacturer’s instructions. In 
detail, the cell culture, fixation, blocking and primary antibody incubation were 
the same as described for immunofluorescence staining on cultured cells. After 
Materials and Methods 
118 
 
primary antibody incubation, cells on coverslips were washed in PBS and 
followed by PLA® Probes incubation for 60 min at 37°C. Then the cells on 
coverslips were washed with Buffer A for 2 × 5 min. Ligation solution was made 
by diluting ligase (1 U/µl) at 1:40 with ligation buffer and then applied to the cells 
and incubated for 30 min at 37°C. Cells were washed in 1x Wash Buffer A for 2 
× 2 min. Amplification solution was made by diluting polymerase (10 U/μl) at 
1:80 in amplification buffer and then applied to the cells and incubated or 100 
min at +37°C. Next cells were washed with wash buffer B for 2 × 10 min and 
then mounted with Duolink In Situ Mounting Medium with DAPI. Images were 
captured with laser scanning microscopy LSM 700 (Carl Zeiss Micro Imaging) 
with a 63× objective and analyzed with ImageJ (National Institutes of Health). 
6.2.12 Chromatin immunoprecipitation (ChIP) and ChIP sequencing 
6.2.12.1 ChIP 
5×106 cells were fixed with 1% formaldehyde for 10min at room temperature. 
Fixation was quenched with 125mM pH 7.5 Tris HCl or glycine followed by 
washes with cold PBS for 3×10min. Cells were further lysed in 600 µl of ice-
cold L1 lysis buffer (Tris pH 8 50mM, EDTA pH8 2mM, NP40 0.1%, glycerol 
10%) for 5 min and nuclei were spun down. Next, nuclei were resuspended in 
600 µl L2 lysis buffer (SDS 1%, EDTA pH8 5mM, Tris pH8 50mM) and DNA was 
sheared by sonication. Extracts were pre-cleared with 80µl protein G beads for 
1h followed by incubation with 10 µg primary antibody overnight at 4 °C and 
binding to 30 µl BSA-coated protein G beads. Immunoprecipitates were washed 
two times with NaCl-washing buffer (0.1% SDS, NP40 1%, 2mM EDTA, 500mM 
NaCl, 20mM Tris pH8), followed by two washes with LiCl-washing buffer (0.1% 
SDS, 1% NP40, 2mM EDTA, 500mM LiCl, 20mM Tris pH8) and eluted with EB-
extraction buffer (TE pH8, 2% SDS). Cross-linking was reverted by incubation 
overnight at 65°C. DNA was purified using Qiagen mini elute PCR purification 
kit (Cat#28004). Immunoprecipitated DNA was either used for qPCR analysis 
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or sequenced on NextSeq500 instrument (Illumina). Sequences of primers 
used for ChIP-qPCR are given in Chapter Primers. 
6.2.12.2 ChIP-Seq data analysis 
ChIP-sequencing reads were mapped to the mouse reference genome mm10 
(UCSC assembly) using the default settings of Bowtie2 (Langmead and 
Salzberg, 2012) the PCR duplicates were removed with MarkDuplicates.jar 
from picard-tools-1.119. Peaks in H3K27me3-ChIP-seq were called using 
findPeaks from homer (-region -size 1000 -minDist 10000 -style histone) using 
the Input as control sample. The common peaks between replicates (n=2) were 
obtained by the use of bedtools intersect (-wa). Distribution of the H3K27me3-
ChIP mapped reads from control and lamin B1 KD MLE12 cells at all peaks in 
MLE12 was performed using ngs.plot (Shen et al., 2014) with mm10. The BAM 
files were normalized to reads per genome coverage (RPGC), by the use of 
BamCoverage from deepTools2 (PMID: 24799436) (-b 20 -smooth 40 -e 150 -
-normalizeTo1x 2652783500).  
6.2.13 In situ nuclear matrix extraction 
Cells on the coverslips were washed and incubated with cytoskeletal (CSK) 
buffer (10 mM PIPES, pH 6.8, 100 mM NaCl, 300 mM sucrose, 1 mM EGTA, 1 
mM MgCl2) supplemented with protease inhibitors and 0.5% Triton X-100 at 
room temperature for 3 min. Chromatin was digested with DNase I (50 ng/μl) in 
DNase I Buffer (10 mM Tris-HCl, pH 7.5, 2.5 mM MgCl2, 0.5 mM CaCl2) at 
room temperature for 30 min. The coverslips were washed with PBS, followed 
by immunostaining. 
6.2.14 Statistical analysis 
Results from quantitative analyses are presented as mean ± standard error of 
the mean (SEM). Statistical analysis was performed using Student’s t-test with 
two-tailed distribution. Sample sizes were determined based on previous 
experience with analogous experiments. The experiments were not 
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randomized and not blinded. For in vivo experiments, animals that 
unexpectedly died were excluded from the analysis. Statistical significance was 
defined as p < 0.05 (*, #: p < 0.05; **, ##: p < 0.01, ***p < 0.001). 
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